Investigating the effect of e-cigarette use on quitting smoking in adults aged 25 years or more using the PATH study [version 3; peer review: 3 approved, 1 not approved]

Peter N. Lee¹, John S. Fry²

¹P.N.Lee Statistics and Computing, Sutton, Surrey, SM2 5DA, UK
²RoeLee Statistics Ltd, Sutton, Surrey, SM2 5DA, UK

Abstract

Background: The evidence on harms and benefits of e-cigarettes partly concerns whether their use encourages smokers to quit. We addressed this using data from the nationally representative PATH study, with detailed accounting for potential confounding variables.

Methods: We considered adults aged 25+. Our original analyses, reported in version 1 of this paper, used data for Waves 1 to 3, separate analyses considering Waves 1 to 2, 2 to 3 and 1 to 3. These related baseline ever e-cigarette use (or e-product use at Wave 2) to quitting at follow-up, adjusting for confounders derived from 55 candidates. Sensitivity analyses omitted ever other product users, linked quitting to current e-cigarette use, and used values of some predictors modified using follow-up data. Additional analyses used data for Waves 1 to 4, separately considering sustained, delayed and temporary quitting during Waves 1 to 3, 2 to 4 and 1 to 4. Sensitivity analyses considered 30-day quitting, restricted attention to smokers attempting to quit, and considered ever smokeless tobacco or snus use.

Results: In the original analyses, unadjusted odds ratios (ORs) of quitting smoking for ever e-cigarette use were 1.29 (95% CI 1.01-1.66), 1.52 (1.26-1.83) and 1.47 (1.19-1.82) for the Wave 1 to 2, 2 to 3, and 1 to 3 analyses. These reduced after adjustment, to 1.23 (0.94-1.61), 1.51 (1.24-1.85) and 1.39 (1.11-1.74). Quitting rates remained elevated in users in all sensitivity analyses. The additional analyses found associations of e-cigarette use with sustained, delayed and temporary quitting, associations little affected by considering 30-day quitting, and only slightly reduced restricting attention to quit attempters. Ever use of smokeless tobacco or snus also predicted increased quitting.

Conclusions: As does most evidence from clinical trials, other analyses of PATH, and other epidemiological studies, our results
suggest using e-cigarettes helps adult smokers to quit.

**Keywords**
Cigarettes, Confounding, Over-adjustment, E-cigarettes, Cessation, Modelling

---

**Corresponding author:** Peter N. Lee ([PeterLee@pnlee.co.uk](mailto:PeterLee@pnlee.co.uk))

**Author roles:** **Lee PN:** Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Fry JS:** Data Curation, Formal Analysis, Investigation, Methodology, Software, Validation, Writing – Review & Editing

**Competing interests:** Both authors are long term consultants to the tobacco industry and organizations, including the funder of this study.

**Grant information:** Financial support for the original analyses based on Waves 1, 2 and 3 was provided by Philip Morris Products SA. Financial support for the additional analysis based on Waves 1 to 4 was provided by P N Lee Statistics and Computing Ltd. While some technical comments were provided by Philip Morris Products SA on drafts of the statistical plan for the original analysis and for version 1 of this publication, the final versions remain the responsibility of the authors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Copyright:** © 2022 Lee PN and Fry JS. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Lee PN and Fry JS. Investigating the effect of e-cigarette use on quitting smoking in adults aged 25 years or more using the PATH study [version 3; peer review: 3 approved, 1 not approved] F1000Research 2022, 9:1099
[https://doi.org/10.12688/f1000research.26167.3](https://doi.org/10.12688/f1000research.26167.3)

**First published:** 07 Sep 2020, 9:1099 [https://doi.org/10.12688/f1000research.26167.1](https://doi.org/10.12688/f1000research.26167.1)
Introduction

It was considered by experts that e-cigarettes cause far less harm to their users than do cigarettes (Nutt et al., 2014), a view supported by limited epidemiological evidence for cardiovascular disease (e.g. Berlowitz et al., 2022; Critcher & Siegel, 2021; Rodu & Plurphanswat, 2020) and respiratory disease (e.g. Antwi & Rhodes, 2022; Osei et al., 2020). However, the introduction of e-cigarettes may theoretically have various other adverse and beneficial effects (Lee et al., 2019). Adverse effects would occur if the use of e-cigarettes encouraged initiation of cigarette smoking, if cigarette smokers intending to quit take up e-cigarettes instead, or if cigarette smokers take up e-cigarettes without reducing their cigarette consumption. Beneficial effects would occur if individuals who would otherwise have continued cigarette smoking switch instead to e-cigarette use, if simultaneous use of e-cigarettes helps cigarette smokers to materially reduce their cigarette consumption, or if use of e-cigarettes helps established cigarette smokers to quit. Here we present results relating to the last of these possibilities, the effect of e-cigarette use on quitting.

Note that the term “quitters”, as used here, relates to those who were smoking at baseline, but not at the end of follow-up, even though they may later relapse to smoking. Some prefer the term “discontinuation of cigarette smoking” (Kasza et al., 2021). Here, we use “quitting” to relate to cigarette smoking, regardless of use of, or switching to, e-cigarettes or other nicotine products, and use “smoking”; not further defined, to relate to cigarettes.

Information on e-cigarette use as an aid to quitting comes from various sources. Evidence from randomised controlled trials comparing smokers assigned a nicotine e-cigarette or a placebo (Baldassarri et al., 2018; Bullen et al., 2013; Caponnetto et al., 2013; Caponnetto et al., 2019; Eisenberg et al., 2020; Masiero et al., 2019), comparing e-cigarettes with NRT (Hajek et al., 2019; Li et al., 2020) or comparing e-cigarettes with nicotine patches (Walker et al., 2020) generally indicates higher quit rates in the nicotine e-cigarette group, although not all the differences cited were statistically significant (at p < 0.05), and one study did not find such higher quit rates (Halpern et al., 2018). A non-randomised study in which smokers were offered free e-cigarettes (Hajek et al., 2015) also found that those who accepted them were more likely to quit. That the evidence from trials suggests higher quit rates in those using e-cigarettes is also consistent with the findings of recent reviews (Grabovac et al., 2020; Hartmann-Boyce et al., 2020; Zhang et al., 2021). While such evidence avoids uncontrolled confounding it can be argued that such trials do not fully reflect what happens in the general population, where smokers choose to try or not try e-cigarettes without being allocated them.

Evidence that smoking rates have declined in the US and UK over a period where e-cigarette use has been increasing (Beard et al., 2020; West et al., 2016b; Zhu et al., 2017) is suggestive of a beneficial effect of e-cigarette use on quitting, but is limited by the difficulty of taking account of other factors affecting smoking rates.

Epidemiological studies are an alternative approach, but while most of such studies show a positive relationship between e-cigarettes and smoking cessation, recent reviews have considered that the evidence is inconclusive due to the low quality of the research (Malas et al., 2016; National Academies of Sciences Engineering and Medicine, 2018). Problems involve the use of cross-sectional studies, the use of unrepresentative populations, the use of non-comparable control groups, failure to limit attention to established e-cigarette users, and the failure fully to take into account the many factors associated with quitting smoking. An expert reaction (West et al., 2016a) made clear that a meta-analysis perversely claiming that e-cigarette use was associated with a reduced risk of quitting (Kalkhoran & Glantz, 2016) suffered from such weaknesses. Restricting attention to cohort studies (other than the study we analyse here) which determine e-cigarette use at baseline and quitting at follow-up, it is clear that by now there are quite a number of studies which report somewhat higher quit rates in those using e-cigarettes, (e.g. (Gomajee et al., 2019; Mantey et al., 2017; Piper et al., 2019; Snow et al., 2018; Young-Wolff et al., 2018; Zhuang et al., 2016), and though there are also many that did
not find any clear association, (e.g. (Bowler et al., 2017; Brose et al., 2015; Chiang et al., 2019; Comford et al., 2021; Flacco et al., 2019; Grana et al., 2014; Gravelvy et al., 2020; Harrington et al., 2015; Jackson et al., 2020; Lozano et al., 2019; Pasquerneau et al., 2017; Sweet et al., 2019; Wang et al., 2017; Wu et al., 2018), it is rare to find studies (Al-Delaimy et al., 2015; Weaver et al., 2018) suggesting that e-cigarettes inhibits quitting.

Here we describe results from a prospective study aimed at avoiding such weaknesses. The main objective of our analyses is to quantify the relationship between e-cigarette use in smokers and subsequent cessation of smoking, with detailed adjustment for the multitude of factors that may differ between e-cigarette users and non-users. Our analyses are based on the Population Assessment of Tobacco and Health (PATH) study, a nationally representative cohort study of tobacco use and how it affects the health of people in the US. Wave 1 was conducted from 12 September 2013 to 15 December 2014, and our analyses are based on data for this Wave and from annual follow-ups. The data files made publicly available include extensive information on use of various types of tobacco products and on numerous variables linked to initiation of tobacco. In order to avoid complexities caused by consideration of younger adults who may only recently have initiated cigarette smoking, possibly only on a temporary basis, attention is limited to adults aged 25 years or more, an age when initiation of cigarettes is less common.

This paper updates an earlier version that described analyses based on follow-up to Wave 3. The current version takes into account comments on the earlier version made by reviewers Chen and Pierce and also includes additional analyses based on follow-up to Wave 4 aimed at providing further understanding (Chen & Pierce, 2020). There are differences of opinion, described later, in how analyses of smoking cessation should be conducted (Glasser et al., 2020; Pierce et al., 2020b) and we consider a variety of approaches.

Methods

Original analyses based on data from Waves 1, 2 and 3

Separate sets of analyses have been conducted for three periods, from Wave 1 to Wave 2 (period 1), from Wave 2 to Wave 3 (period 2) and from Wave 1 to Wave 3 (period 3). The analyses are based on individuals with relevant data available at Waves 1, 2 and 3 on smoking and e-cigarette use, and take account of the person-based weights of the baseline population. All analyses are limited to individuals aged 25 years or over at baseline.

Some studies of data from Waves 1 to 3 of the PATH study (Benmarhnia et al., 2018; Pierce et al., 2020a; Watkins et al., 2020) have limited analyses to quit attempters, but others (Berry et al., 2019; Kalkhoran et al., 2020; Verplaetse et al., 2019) have not. Although such a limitation more closely mimics randomised control trials (Pierce et al., 2020c) we preferred not to do so in our original analyses, and to avoid bias by adjusting for aspects of quitting in analyses. Our approach uses a larger sample size and provides results that are more representative of the whole population of baseline smokers.

A current cigarette smoker is a “current established cigarette user” defined as “has ever smoked a cigarette, has smoked more than 100 cigarettes in life time, and currently smokes every day or some days”, while a former cigarette smoker is a “former established cigarette user” defined as “has ever smoked a cigarette, has smoked more than 100 cigarettes in life time, and now does not smoke at all”. Those who are neither current nor former cigarette smokers at baseline are not considered in the analyses.

A current e-cigarette user is a “current established e-cigarette user” defined as “has ever used an e-cigarette, has used fairly regularly and uses every day or some days”, while a former e-cigarette user is a “former established e-cigarette user” defined as “has ever used an e-cigarette, has used fairly regularly, and currently does not use at all”. An ever e-cigarette user is either a current or former e-cigarette user. At Wave 2 those who smoked other e-products (such as e-cigs, e-pipes or e-hookahs) are also included, so the definition relates to e-product rather than e-cigarette use.

For each period, the analyses relate ever e-cigarette use at baseline to the probability of being an established former smoker at follow-up (referred to subsequently as either “quitting” or “quitting during follow-up”), with adjustment for predictor variables measured at baseline. The predictor variables have been selected from a pre-defined list of candidates classified into eight groups: demographics (A); general aspects of smoking (B); aspects of smoking specifically related to quitting (C); smoking by family and friends (D); awareness of hazards (E); health status (F); alcohol and drugs (G); and others (H).

The specific predictor variables are listed in the Results section, with fuller details of their definition given in the Extended data. While the variables were chosen as being suggested by the literature as being related to smoking, the Extended data also provides information, based on Wave 1, of their association with ever e-cigarette use. As shown there, ever use was highly significantly (p < 0.001) more frequent in the young and in females, and after adjustment for age and sex, was also highly significantly related to a range of the predictor variables considered, being less frequent in Hispanics and Blacks, and more frequent in those with more income or education, those who ever use other tobacco products, those who have a perceived greater need for tobacco, those who have tried to quit more often, those who plan to quit, those who find it hard to stop smoking and those who have used quitting aids. Users were also clearly more likely to have significant problems more recently with sleeping, anxiety and distress, to see a doctor more often, to use the internet often, and to use various different types of drugs (but not cocaine or crack). At most weak relationships were seen with smoking by family and friends, awareness of the hazards of smoking, use of alcohol, body mass index, or self-perception of physical health or quality of life. Little relationship was also seen between ever e-cigarette use and daily cigarette consumption, a finding which was reported earlier (Lee et al., 2020) where it was suggested that it was explained by smokers taking up e-cigarettes having higher
consumption initially, reduced by partial replacement of cigarettes by e-cigarettes.

Where the baseline of the period studied is Wave 1, the values of the predictor variables used are as recorded at Wave 1. Where it is Wave 2, the values of some variables are amended to take into account data from Wave 1, as described in the Extended data.

For each period, the analysis was conducted in seven stages, preliminary counts and six further steps, each involving weighted logistic regression analyses.

Counts Restricted to individuals who were current cigarette smokers at baseline, a frequency table was prepared, separated by quitting during follow-up, of e-cigarette use at baseline by each of the adjustment variables. Missing values are shown, to indicate variables with high levels of missing values requiring special consideration in analysis.

Step 1 This is conducted in eight parts, each part corresponding to a group of predictor variables (A to H). For each part, the regressions first relate each predictor variable individually to quitting, with stepwise forward multiple regressions then carried out, with the most significant predictor variable introduced first, then the next most significant, and so on, until no more variable can be added that is significant at p < 0.01.

Step 2 This is in three sections, each involving stepwise forward multiple regressions. The first section considers all the variables found to be significant in Step 1 from groups A, B and C, the second considers those significant from groups D, E and F, and the third those significant from groups G and H.

Step 3 A final stepwise regression considers all the predictor variables remaining as significant in step 2. This generates a final list of predictors to be considered when relating ever e-cigarette use to quitting.

Each analysis in steps 1 to 3 is restricted to those with non-missing data for all the predictor variables considered in the particular analysis.

The final three steps are then based on all individuals with data on all the predictor variables in the final list.

Step 4 An unadjusted analysis relates ever e-cigarette use to quitting.

Step 5 Stepwise regression analyses are run, introducing the predictor variables in the final list first, and then adding ever e-cigarettes as a predictor.

Step 6 Stepwise regressions similar to those in step 5 are run, but introducing ever e-cigarette use first rather than last.

The principal results produced by the regression analyses are the odds ratios (ORs) and 95% confidence intervals (CIs) relating to each predictor of interest, and the significance of introducing that predictor into the model.

While the main analyses relate quitting cigarettes during follow-up to ever e-cigarette use at baseline and the predictor variables considered include use of nicotine products other than cigarettes or e-cigarettes, four sensitivity analyses (S1 to S4) were also conducted, which are intended to give additional information on how dependent the ORs derived in the main analysis are on exactly how they are conducted. S1 restricts attention to individuals who have never used other nicotine products; S2 links quitting to current (rather than ever) e-cigarette use at baseline; S3 adjusts, where necessary, for variables which take account of data recorded at the end of follow-up rather than just at baseline; and S4, which applies only to the analyses based on quitting between Waves 1 and 3, additionally adjusts for whether the individual had already quit by Wave 2.

In each of S1 to S4 the analyses run were as in steps 4 to 6 of the main analyses and used the final set of predictor variables derived for the period they related to.

For most of the 55 predictor variables considered, there were relatively few missing values, and the regressions could be run excluding the individuals with missing values for the predictors considered without material loss of power. However, for two predictors, where there were about 8% of missing values, individuals with missing data were assigned average values. Thus, for household income in the past 12 months, where data were recorded in five increasing levels, individuals recorded as unknown were assigned an income in the third level, $25,000 to $49,999, while for poverty status, where data were recorded in three levels, <100%, 100–199% and 200+%, of the poverty guideline, individuals recorded as unknown were assigned a status in the second level. For living with a regular smoker who smoked inside your home during childhood, where about 16% of individuals were classified as “not ascertained” rather than “yes” or “no”, this answer was included as a separate level, thus the predictor was treated in analysis as having three levels.

For some predictors with multiple levels, the regression analyses were based on a single trend variable. This was only appropriate where the predictor variable represented increasing (or decreasing) levels of a characteristic.

Generally, the analyses were based on the values of predictors as recorded at the baseline Wave. Where the baseline Wave was Wave 2, however, and data were not available at Wave 2, Wave 1 data were used if appropriate. Also, if the Wave 2 predictor related to ever having done something, particularly when the variable concerned action in the last 12 months, individuals were counted as ever having done so if this was reported at Wave 1 or 2.

Further details of the process, particularly for the calculation of numbers of cigarettes per day, are given in the Extended data.
Additional analyses based on data from Waves 1 to 4
While our original analyses only consider overall quitting, our additional analyses separately consider sustained quitting (quitting seen at all follow-up years), temporary quitting (quitting seen at some follow-up years, but not the final one) and delayed quitting (quitting seen at final follow-up, but not all other years since baseline). We also carry out sensitivity analyses with quitting defined as having quit for 30 days at the relevant Wave, and restricting attention to smokers attempting to quit. For comparative purposes, we also carry out analyses comparing rates of sustained, temporary and delayed quitting smoking in smokeless tobacco users and snus users. Much of the methodology is as described for the analyses based on data from Waves 1, 2 and 3.

Separate sets of analyses have been carried out for three periods: from Wave 1 (baseline) to Waves 2 and 3 (follow-up period); from Wave 2 to Waves 3 and 4; and from Wave 1 to Waves 2, 3 and 4. Each analysis is based on individuals with relevant data available on smoking and e-cigarette use at all the Waves considered in that analysis, is limited to individuals aged 25 years or over at baseline, and takes account of the person-based weights of the baseline population. Each analysis restricts attention to baseline established cigarette smokers as defined earlier and compares ever to never regular e-cigarette users at baseline in regard to the probabilities of persistent quitting, temporary quitting or delayed quitting. Adjustment for potential confounding variables is as described above, with logistic regression analyses being carried out to determine which of a list of candidate predictors should be included in the model relating e-cigarette use to the three different definitions of quitting.

For each follow-up period, four sensitivity analyses have been carried out:

Sensitivity analysis 5: The definition of quitting relates to being a 30-day quitter at the relevant Wave, the analysis otherwise being identical;

Sensitivity analysis 6: The analyses are restricted to those cigarette smokers who ever quit or attempted to quit in the year following baseline;

Sensitivity analysis 7: Instead of comparing never and ever users of e-cigarettes, never and ever users of smokeless tobacco are compared.

Sensitivity analysis 8: Here, never and ever users of snus are compared.

Results
Analyses based on data from Waves 1, 2 and 3
Table 1 shows the predictor variables used in the final regression analysis or excluded at various stages of the preliminary analyses.

For the analyses based on Waves 1 and 2, for example, 54 predictors were considered, 11 in group A, 8 in B, 8 in C, 4 in D, 4 in E, 8 in F, 9 in G, and 2 in H. Of the 55 predictors

| Table 1. Predictor variables included in the final regression analysis (Y) or excluded at steps 1, 2 or 3 (X1, X2, X3). |
|---------------------------------------------------------------|
| Levels of variable | Wave 1 to 2 quitting | Wave 2 to 3 quitting | Wave 1 to 3 quitting |
| All smokers at baseline | 8,924 | 7,825 | 8,924 |
| Not followed at subsequent waves | 2,421 (27.1%) | 978 (12.5%) | 2,434 (27.3%) |
| Smokers at baseline | 6,503 | 6,847 | 6,490 |
| Quit by follow-up | 655 (10.1%) | 633 (9.2%) | 901 (13.9%) |
| Demographics (A) | | | |
| Age range | 5 | Y | X3 |
| Gender | 2 | X1 | X1 |
| Hispanic origin | 2 | X2 | X2 |
| Race | 3 | X1 | X1 |
| Census region | 4 | X1 | X1 |
| Total household income | 5T | Y | Y |
| Poverty status | 3T | X1 | - |
| Total number in the household | 5T | X1 | - |
| Highest grade level of school completed | 6T | X2 | Y |
| Currently enrolled in a degree program | 2 | X1 | X1 |
| **Current employment status** | Levels of variable | Wave 1 to 2 quitting | Wave 2 to 3 quitting | Wave 1 to 3 quitting |
|-------------------------------|--------------------|----------------------|----------------------|----------------------|
|                              | 8                  | X1                   | X1                   | X1                   |

**Aspects of smoking – general (B)**

| **Age range started smoking cigarettes fairly regularly** | 6 | X1 | X1 | X1 |
|----------------------------------------------------------|---|----|----|----|
| **Current someday cigarette smokers**                    | 2 | Y  | Y  | Y  |
| **Cigarettes per day**                                   | C | Y  | X3 | Y  |
| **Ever used other tobacco products**                      | 2 | X1 | X1 | X1 |
| **Frequently crave tobacco product(s)**                   | 5T| X1 | X1 | X1 |
| **Usually wants to smoke/use tobacco right after waking**| 5T| Y  | Y  | Y  |
| **After not smoking for a while, need to smoke to avoid discomfort** | 5T| X1 | X1 | X1 |
| **Can only go a couple of hours without smoking/tobacco**| 5T| X1 | X1 | X1 |

**Aspects of smoking – specifically related to quitting (C)**

| **Have tried to quit completely**                         | 2 | Y  | Y  | Y  |
|-----------------------------------------------------------|---|----|----|----|
| **Would find it hard to stop smoking/tobacco for a while**| 5T| X2 | X2 | X2 |
| **Times stopped smoking for one day or more in past year**| 4T| X1 | X1 | X1 |
| **Ever used a nicotine patch, gum, inhaler, nasal spray, lozenge or pill** | 2 | X1 | X1 | X1 |
| **Ever used Chantix, varenicline or bupropion (Wellbutrin, Zyban)** | 2 | X1 | X1 | Y  |
| **Plans to quit smoking/using tobacco product(s) for good**| 2 | X1 | X1 | X1 |
| **Smoking/using tobacco product(s) really helps me feel better if feeling down** | 5 | X1 | X1 | X1 |
| **Extent disapproval of smoking from friends and family led to thinking about quitting in past year** | 3T| X1 | -  | X1 |

**Smoking by family and friends (D)**

| **Rules about smoking a combustible tobacco**             | 3T| Y  | X3 | Y  |
|-----------------------------------------------------------|---|----|----|----|
| **Anyone who lives with you now smoke cigarettes**        | 2 | X3 | X1 | X2 |
| **Most people I spend time with are tobacco users**       | 5T| X3 | X3 | X2 |
| **Lived with regular smoker who smoked inside your home during childhood** | 3 | X1 | Y  | X2 |

**Awareness of hazards of smoking (E)**

| **How often have you seen a list of chemicals in tobacco products in last 12 months** | 5T| X1 | X1 | X1 |
|----------------------------------------------------------------------------------------|---|----|----|----|
| **How often noticed health warnings on cigarette packages in past 30 days**            | 5T| X1 | X1 | X1 |
| **Overall opinion of tobacco**                                                          | 5T| Y  | X3 | X2 |
| **Perception of harmfulness of cigarettes to health**                                   | 5T| X1 | X1 | Y  |

**Health status (F)**

| **Saw a medical doctor in past 12 months**                                            | 2 | X2 | X1 | X1 |
|----------------------------------------------------------------------------------------|---|----|----|----|
| **Body mass index**                                                                     | C | Y  | X3 | X1 |
| **Self-perception of physical health**                                                  | 5T| X1 | X2 | X1 |
listed in Table 1, there was one variable in group H with no Wave 1 data. Of the 54 predictors considered in the Wave 1 and 2 analyses, 37 were excluded at step 1, marked X1 in Table 1. A further 4 were excluded at step 2 (X2). This left 13 variables considered in step 3, of which 4 were excluded (X3), with 9 included in the final model (Y).

For the analyses based on Waves 2 and 3 there were data available on 51 predictors, with 45 excluded (34 X1, 3 X2 and 8 X3) and 6 included in the final model. For those based on Waves 1 and 3 there were data on 54 predictors, with 46 excluded (35 X1, 8 X2 and 3 X3) and 8 included in the final model.

Table 2 summarises the results of the main analyses. Here, and in later tables, ORs significant at p<0.05 are shown in boldface. Each analysis was based on between 6,000 and 7,000 adults with the percentage quitting varying from 9.1% to 13.1%. The unadjusted gateway-out effect varied from 1.29 to 1.52 in the three analyses. Adjustment only slightly reduced the estimates, the fully adjusted ORs being 1.23 (95%CI 0.94-1.61) for Wave 1 to 2, 1.51 (1.24-1.85) for Wave 2 to 3, and 1.39 (1.11-1.74) for Wave 1 to 3.

Table 3 shows the full models used, showing the effect estimates for each of the predictor variables used to adjust the relationship of ever regular e-cigarette use to quitting. Where the same adjustment variable was included in each model, the effect estimates were generally quite similar and always in the same direction. As regards aspects of smoking, smokers were found to be less likely to quit if they were everyday smokers, were more likely to smoke right after waking up, had not previously tried to quit, smoked more cigarettes per day, lived in a home with more relaxed rules about smoking, lived with a smoker in childhood, had a better opinion of tobacco, or had a lesser perception of cigarettes as harmful. They were also less likely to quit if they had ever used the pharmaceutical aids to quitting Chantix, varenicline or buproprion (Wellbutrin, Zyban). Smokers were also less likely to quit if they were worse off and worse educated. Older age (particularly above age 74 years) and greater BMI were also associated with a greater likelihood to quit.

Table 4 summarises the results of the sensitivity analyses, showing the estimated ORs in each case from the fully adjusted models.
### Table 2. Effect of adjustment on the OR (95% CI) for the relationship of ever regular e-cigarette use* to quitting.

|                        | Wave 1 to 2 quitting | Wave 2 to 3 quitting | Wave 1 to 3 quitting |
|------------------------|----------------------|----------------------|----------------------|
| **Unweighted numbers** |                      |                      |                      |
| Total – in baseline    | 6,503                | 6,847                | 6,490                |
| Excluded from final regression | 262 (4.0%)     | 89 (1.3%)            | 175 (2.7%)          |
| Included in final regression | 6,241               | 6,758                | 6,315                |
| Total ever e-cigarette users – in baseline | 727                | 1,306                | 726                  |
| Excluded from final regression | 24 (3.3%)      | 12 (0.9%)            | 16 (2.2%)           |
| Included in final regression | 703                 | 1,294                | 710                  |
| Quit                   | 78 (11.1%)           | 160 (12.4%)          | 118 (16.6%)          |
| Total never e-cigarette users – in baseline | 5,776         | 5,541                | 5,764                |
| Excluded from final regression | 238 (4.1%)   | 77 (1.4%)            | 159 (2.8%)          |
| Included in final regression | 5,538              | 5,464                | 5,605                |
| Quit                   | 503 (9.1%)           | 456 (8.3%)           | 711 (12.7%)          |
| **Weighted ORs and 96% CIs** |                  |                      |                      |
| Unadjusted             | 1.29 (1.01-1.66)    | 1.52 (1.26-1.83)    | 1.47 (1.19-1.82)    |
| Adjusted for four most important variables | 1.17 (0.90-1.52) | 1.54 (1.26-1.88)    | 1.43 (1.14-1.78)    |
| Adjusted for all variables included in final list | 1.23 (0.94-1.61) [9 variables] | 1.51 (1.24-1.85) [6 variables] | 1.39 (1.11-1.74) [8 variables] |

*Where the baseline is Wave 1, the predictor is ever regular e-cigarette use, where it is Wave 2, it is ever regular e-product use

### Table 3. ORs related to quitting cigarettes in the final models used in the main analysis.

|                        | Wave 1 to 2 quitting | Wave 2 to 3 quitting | Wave 1 to 3 quitting |
|------------------------|----------------------|----------------------|----------------------|
| Ever regularly used e-cigarette = yes | 1.23 (0.94-1.61) | **1.51** (1.24-1.85) | **1.39** (1.11-1.74) |
| Age range              |                      |                      |                      |
| 25–34                  |                      | Reference            | Not included         | Not included         |
| 35–44                  | 0.95 (0.74-1.21)     |                      |                      |
| 45–54                  | 0.85 (0.66-1.10)     |                      |                      |
| 55–64                  | 1.20 (0.92-1.57)     |                      |                      |
| 65–74                  | 1.42 (0.98-2.06)     |                      |                      |
| 75+                    | **3.31** (1.84-5.97) |                      |                      |
| Total household income (per level increasing) | **1.14** (1.05-1.23) | **1.16** (1.07-1.25) | **1.21** (1.13-1.29) |
| Current some day smoker = no | **0.43** (0.34-0.54) | **0.36** (0.30-0.44) | **0.52** (0.43-0.64) |
| Highest grade or level at school completed (per level increasing) | Not included | **1.10** (1.03-1.18) | Not included |
| Per cigarette per day  | **0.97** (0.96-0.99) | Not included         | **0.97** (0.96-0.98) |
Wave 1 to 2 quitting | Wave 2 to 3 quitting | Wave 1 to 3 quitting
---|---|---
**N (n)** | **OR (95% CI)** | **N (n)** | **OR (95% CI)** | **N (n)** | **OR (95% CI)**

**Main model**

| 581 (78) | 1.23 (0.94-1.61) | 616 (160) | 1.51 (1.24-1.85) | 829 (118) | 1.39 (1.11-1.74)

**Sensitivity analysis 1**
(Omitting ever users of other nicotine products)

| 148 (16) | **2.04** (1.15-3.62) | 122 (20) | 1.69 (0.96-2.99) | 217 (25) | **2.22** (1.38-3.57)

**Sensitivity analysis 2**
(Linking quitting to current rather than ever e-cigarette use at baseline)

| 581 (64) | **1.41** (1.06-1.89) | 615 (89) | **1.30** (1.01-1.67) | 829 (95) | **1.56** (1.21-2.00)

**Sensitivity analysis 3**
(Adjusting for variables taking account of data recorded at both baseline and end of follow-up)

| 655 (82) | 1.20 (0.92-1.57) | 591 (160) | **1.66** (1.35-2.04) | 901 (121) | **1.43** (1.14-1.79)

**Sensitivity analysis 4**
(Adjust also for quitting by Wave 2)

| Not applicable | Not applicable | 443 (64) | **1.43** (1.11-1.84)

**Table 4. Comparing adjusted ORs for the effect of e-cigarette use on quitting in the main and sensitivity analyses.**

* N = total number quitting

* n = number of quitters among e-cigarette users (current users in sensitivity analysis 2, ever users otherwise)

**Analysis.** The first line of results (“Main model”) repeats the estimates shown in Table 3.

Sensitivity analysis 1 excludes those who had ever used other nicotine products. The number of quitters is substantially reduced, as is the number using e-cigarettes (or e-products). However, the OR is increased, with ever regular users of e-cigarettes about twice as likely to quit cigarettes by the end of the follow-up period, though the CIs of the ORs are relatively wide.

In sensitivity analysis 2, quitting is linked to current rather than ever e-cigarette use. Here the ORs tend to be somewhat higher than in the main analysis (though not for the Wave 2 to 3 analysis).

The results for both sensitivity analysis 1 and 2 seem consistent with smokers being more likely to quit if, at baseline, e-cigarettes formed a more important part of the total tobacco use.

Sensitivity analysis 3 adjusts, where necessary, for variables which are modified to take account of data recorded at the end of follow-up, and not just at baseline, in an attempt to minimise “residual confounding”. The ORs were quite similar to those in the main analysis for Wave 1 to 2, or Wave 1 to 3 quitting, but were somewhat increased for Wave 2 to 3 quitting.

Sensitivity analysis 4, only applicable to the Wave 1 to 3 quitting analyses, adjusted also for having quit by Wave 2. This slightly increased the estimate from the main analysis.
Analyses based on data from Waves 1 to 4

Table 5 shows which predictor variables were included in the regression analysis for the three main analyses and all the sensitivity analyses. Seven predictor variables were included in at least 10 of the 15 regression analyses, with a further three included in at least five, and 11 other predictors occurring in at least one. The direction of the associations was generally consistent, with quitting cigarettes more likely in those who, for example, smoked someday rather than every day, had previously tried to quit, who were less likely to smoke right after waking up, were aged 75 or more, had a higher income, and who smoked less cigarettes a day.

Table 6 shows the results of the main analyses. The nine unadjusted ORs for each combination of period and type of quitting were all greater than 1.00, ranging from 1.10 for temporary quitting for Wave 1 to 2/3, to 1.68, for temporary quitting for Wave 2 to 3/4. Adjustment for all the variables included in the final list generally slightly decreased the ORs, though there were some exceptions, with the adjusted OR significant

| Variable                              | Levels of Variable | Wave 1 to 2/3 quitting | Wave 2 to 3/4 quitting | Wave 2/3/4 quitting |
|---------------------------------------|--------------------|------------------------|------------------------|--------------------|
|                                       |                    | M S5 S6 S7 S8 M S5 S6 S7 S8 M S5 S6 S7 S8 |                       |                    |
| Age range                             |                    | 6 8 6 8 6 7 6 7 7 8 |                       |                    |
| Gender                                |                    | 2                      |                       |                    |
| Total household income                | T                  | 7 3 4 10 4 1 1 1 1 1 10 4 5 10 10 |                       |                    |
| Currently enrolled in a degree program|                    | 2                      |                       |                    |
| Current someday cigarette smokers     |                    | 2 1 1 1 1 1 2 2 2 2 1 1 1 1 1 |                       |                    |
| Cigarettes per day                    | C                  | 2 2 2 2 2 2 2 6 2 2 2 2 |                       |                    |
| Frequently crave tobacco product(s)   | T                  | 5 2 2 2 2 2 2 2 2 2 2 |                       |                    |
| Usually wants to smoke/use tobacco right after waking | T | 5 7 3 4 3 3 3 7 7 7 |                       |                    |
| Have tried to quit completely         |                    | 2 3 4 5 5 5 4 3 8 |                       |                    |
| Would find it hard to stop smoking/tobacco for a while | T | 5 6 |                       |                    |
| Plans to quit smoking/using tobacco product(s) for good | 2 | 3 3 |                       |                    |
| Rules about smoking a combustible tobacco | T | 3 4 7 5 3 5 |                       | 4 7 4 3 4 |
| Most people I spend time with are tobacco users | T | 5 |                       | 5 5 5 |
| Lived with regular smoker who smoked inside your home during childhood | 3 | 4 3 4 4 5 |                       |                    |
| How often have you seen a list of chemicals in tobacco products in last 12 months | T | 7 |                       |                    |
| How often noticed health warnings on cigarette packages in past 30 days | T | 9 |                       |                    |
| Overall opinion of tobacco            | T                  | 5 6 5 6 6 6 |                       |                    |
| Body mass index                       | C                  | 9 7 9 7 6 8 5 6 6 9 7 9 9 |                       |                    |
| Becoming very distressed with something reminded of past | T | 4 7 |                       |                    |
| Ever used marijuana, hash, THC or grass | 2 | 4 |                       | 3 |
| Hours spent watching TV on a typical day | T | 8 |                       | 8 |
| Total adjustment variables            |                    | 9 7 7 10 7 8 9 7 7 8 10 8 9 10 10 |                       |                    |

C = continuous variable, M = Main analysis, S = Sensitivity analysis, T = treated as a linear trend in regressions
(at p < 0.05) in seven of the nine cases. Notably all the fully adjusted ORs for sustained quitting were positive and significant, with estimates close to 1.50 for each period studied.

Table 7 summarises the adjusted results for the main and sensitivity analyses, again for each combination of period and type of quitting. Of the 45 ORs, 42 are positive (> 1.0) with 20 of these statistically significant, and three are negative (< 1.0) with none of these significant. Associations are clearly evident for 30-day quitting, and when restricted by those attempting to quit in the year following baseline. Interestingly, associations are seen, in some cases larger than for e-cigarette use, both for smokeless tobacco and for snus use.

Discussion
Discussion of results based on Waves 1, 2 and 3
The first set of analyses described in this report summarise evidence from Waves 1, 2 and 3 of the US PATH study relating to the possibility that e-cigarette use may increase the likelihood of smokers quitting cigarettes. All of the adjusted ORs estimated, which as shown in Table 4 varied between 1.20 and 2.22, were consistent with this possibility, although not all the estimates were statistically significant at p < 0.05. Compared to the estimates from the main model, which related ever e-cigarette use at baseline to quitting by follow-up, ORs were increased (though based on far fewer quitters) when those who had ever used other products were omitted from the analysis. The ORs were also increased, in the analysis with Wave 1 as the baseline, when quitting was linked to current rather than ever e-cigarette use. In both the sensitivity analyses where the ORs were increased, e-cigarette use would have formed a greater proportion of current tobacco use at baseline.

Eight other related analyses based on the first three Waves 1 of the PATH study have previously been published. The first seven analyses summarised below (Benmarhnia et al., 2018; Berry et al., 2019; Glasser et al., 2021; Kalkhoran et al., 2020; Kurti et al., 2020; Verplaetse et al., 2019; Watkins et al., 2020) are consistent with e-cigarette use increasing the probability of quitting cigarettes, despite variation in whether Wave 3 data has been used or not, whether analyses are restricted to those attempting quitting at baseline, the definition of abstinence used, the
### Table 7. Comparing adjusted ORs for the effect of e-cigarette, smokeless tobacco or snus use on quitting in the main and sensitivity analyses.

| Type of quitting | Model  | Wave 1 to 2/3 quitting | Wave 2 to 3/4 quitting | Wave 1 to 2/3/4 quitting |
|------------------|--------|------------------------|------------------------|--------------------------|
|                  |        | N (n) | OR (95% CI) | N (n) | OR (95% CI) | N (n) | OR (95% CI) |
| Delayed          | Main   | 448 (65) | 1.38 (1.03-1.85) | 392 (91) | 1.25 (0.97-1.62) | 606 (89) | 1.43 (1.10-1.85) |
|                  | Sensitivity 5 | 377 (56) | 1.50 (1.11-2.04) | 352 (84) | 1.28 (0.99-1.67) | 538 (83) | 1.53 (1.18-1.99) |
|                  | 6      | 261 (40) | 1.26 (0.86-1.86) | 222 (61) | 1.21 (0.87-1.66) | 344 (50) | 1.21 (0.85-1.72) |
|                  | 7      | 449 (41) | 1.16 (0.71-1.90) | 396 (42) | 1.07 (0.77-1.51) | 603 (61) | 1.42 (1.05-1.91) |
|                  | 8      | 476 (21) | 1.79 (0.91-3.53) | 394 (18) | 1.16 (0.68-1.97) | 608 (22) | 1.32 (0.80-2.19) |
| Temporary        | Main   | 201 (24) | 0.93 (0.59-1.46) | 195 (55) | 1.60 (1.14-2.25) | 349 (48) | 1.26 (0.89-1.77) |
|                  | Sensitivity 5 | 142 (20) | 1.29 (0.79-2.09) | 134 (39) | 1.69 (1.14-2.53) | 258 (37) | 1.31 (0.90-1.91) |
|                  | 6      | 210 (24) | 0.93 (0.58-1.47) | 195 (55) | 1.24 (0.87-1.75) | 282 (44) | 1.48 (1.01-2.16) |
|                  | 7      | 199 (18) | 1.16 (0.69-1.96) | 192 (30) | 1.79 (1.19-2.68) | 345 (32) | 1.14 (0.75-1.73) |
|                  | 8      | 208 (9) | 1.96 (0.97-3.96) | 193 (19) | 3.29 (1.98-5.46) | 347 (16) | 1.93 (1.08-3.43) |
| Sustained        | Main   | 380 (54) | 1.51 (1.09-2.08) | 344 (86) | 1.48 (1.13-1.94) | 272 (33) | 1.52 (1.02-2.26) |
|                  | Sensitivity 5 | 289 (35) | 1.36 (0.94-1.97) | 243 (62) | 1.50 (1.11-2.02) | 206 (22) | 1.46 (0.93-2.31) |
|                  | 6      | 425 (57) | 1.45 (1.03-2.05) | 350 (87) | 1.17 (0.88-1.56) | 281 (33) | 1.45 (0.95-2.22) |
|                  | 7      | 385 (38) | 1.57 (1.04-2.35) | 343 (37) | 1.04 (0.71-1.50) | 269 (28) | 1.76 (1.14-2.72) |
|                  | 8      | 423 (19) | 2.30 (1.28-4.14) | 345 (12) | 0.80 (0.43-1.52) | 272 (11) | 1.99 (0.99-3.98) |

N = total number quitting for the given type  
n = number of quitters among users

Main                   Comparison of ever and never regular e-cigarette users  
Sensitivity 5          As main, but relates to 30-day quitting at the relevant wave  
Sensitivity 6          As main, but excluding those not attempting to quit in first year of follow-up  
Sensitivity 7          As main, but comparison of ever and never smokeless tobacco users  
Sensitivity 8          As main, but comparison of ever and never snus users

Confounding variables adjusted for, the age range of the population studied, and other analytical details. However, a final analysis by Pierce et al. (2020a) only reported a small and non-significant increase in quitting related to e-cigarette use.

An analysis of 3,093 quit attempters based on adult data from Waves 1 and 2 (Benmarhnia et al., 2018) considered two endpoints – abstinence from smoking for at least 30 days and reduced cigarette consumption – and reported a significant increase in both endpoints related to using e-cigarettes to quit during the previous year, but no significant increase in either endpoint related to the use of approved pharmaceutical aids.

Another analysis based on Waves 1 and 2 (Berry et al., 2019), here limiting attention to adults aged 25 years or more, studied factors related to 30-day cigarette cessation and to at least a 50% reduction in cigarette consumption in multivariable logistic regression analyses, which included a number of the variables included as predictors in our analyses. While the model included e-cigarette use, this was defined not at baseline, but as new e-cigarette use at Wave 2. In this analysis large ORs were reported for everyday e-cigarette use both for cessation (7.88, 95% CI 4.45-13.95) and for a 50% reduction in cigarette consumption (5.70, 3.47-9.35).

A further analysis based on Waves 1 and 2 (Verplaetse et al., 2019) considered adults aged 18+ years and reported that, compared to those who had never used e-cigarettes at Wave 1, quitting was increased in Wave 1 daily users (OR 1.56, 95%CI 1.12-2.18) but not in Wave 1 nondaily users (0.83, 0.68-1.02). Age, race and education were the only adjustment variables considered.

Based mainly on data from Waves 1 and 2, an analysis limited to women aged 18-49 years (Kurti et al., 2020) and adjusted for demographic and psychosocial characteristics and pregnancy status concluded that use of e-cigarettes by smokers at Wave 1 was associated with an increased odds of quitting at Wave 2.
Analyses based on data from Waves 1, 2 and 3 (Watkins et al., 2020), conducted separately for adults aged 18-24 years and 25+ years, studied the relation of a variety of cessation strategies to short-term cessation (quit at Wave 2) and long-term cessation (quit at both Waves 2 and 3). Adjustments were made for a range of covariates. The authors reported that “substitution with e-cigarettes” did not predict long-term cessation but predicted short-term cessation for older daily smokers of 5 or more cigarettes a day.

An analysis based on data for adults from Waves 1, 2 and 3 (Kalkhoran et al., 2020), related current e-cigarette use at Wave 1 (defined as daily, non-daily or none) in cigarette smokers at Wave 1 to three cigarette abstinence endpoints: at Wave 2, at Wave 3 or at Waves 2 and 3 (prolonged abstinence). Adjustments were made for a fixed set of variables: age, sex, race/ethnicity, education, income, cigarettes per day, and having a first cigarette within 30 minutes of waking. Non-daily e-cigarette use was only associated with a small, non-significant increase in each of the abstinence endpoints, but daily e-cigarette use was associated with a clear increase in all three endpoints, with adjusted ORs of 1.53 (95%CI 1.04-2.23) for Wave 2 abstinence, 1.57 (1.12-2.21) for Wave 3 abstinence, and 1.77 (1.08-2.89) for abstinence at both Waves 2 and 3. These results particularly seem quite similar to ours.

Another analysis of data from Waves 1, 2 and 3 (Glasser et al., 2021) found that smokers using e-cigarettes daily or increasing to daily use over the 3 waves were 2-4 times more likely to have quit smoking, both in the short and the long-term (p < 0.001). However, smokers using e-cigarettes less often or not at all were less likely to quit.

A fourth analysis based on data from Waves 1, 2 and 3 (Pierce et al., 2020a) restricted attention to adult (ages 18+) smokers identified at Wave 1 who reported a quit attempt before Wave 2 and completed Wave 3. 12-month abstinence at Wave 3 among e-cigarette users was slightly but non-significantly reduced as compared both to users of pharmacotherapy to quit or no product.

The strengths of our work include the use of a prospective study design based on a study population which is reasonably representative of the US (though subject to some selection bias), and analyses which take account of a very large number of other predictors of quitting, and restrict attention to established e-cigarette use.

Limitations relate to the relatively small number of quitters, leading to the decision not to study heterogeneity of the results by basic variables, such as sex, race or age group. Our decision to limit attention to those aged at least 25 years was based on the desire not to include young smokers whose smoking habits were not well established.

Discussion of additional results based on Waves 1 to 4
A publication based on the PATH study that reported a positive association of e-cigarette use with quitting by Glasser et al. (2021) was criticised by Pierce et al. (2020b), who themselves had found no significant association (Pierce et al., 2020a), on the grounds that they included smokers not wanting to quit or making a quit attempt, and used a design that did not assess e-cigarette exposure before the smoking cessation outcome was assessed. In their reply, Glasser et al. (2020), pointed out that asking different questions requires different methods, and that while the study by Pierce et al. (2020a) was “framed as an intervention study”, their study “attempted to answer a broader question; the impact of e-cigarettes on cigarette smoking cessation among the full sample of smokers in the PATH study.” Our first set of analyses did assess e-cigarette exposure before the smoking cessation outcome, so no revised analysis was necessary here. However, though our analyses were also an attempt to answer the broader question of Glasser et al., we did include a sensitivity analysis (6) in our analyses based on Waves 1 to 4 to show the effect of limiting attention to those considering quitting smoking. Conducting such a sensitivity analysis had also been noted in version 1 of this paper as an option for consideration in further analysis, using the additional data from Wave 4. Version 1 had also noted the possibility of studying sustained quitting, considered in the additional results along with delayed and temporary quitting, and of analysing 30 day quitting, considered in sensitivity analysis 5.

The additional results based on Waves 1 to 4, illustrate that there is an association of e-cigarette use at baseline with subsequent quitting, whether this be delayed, temporary or sustained, that the association is little affected by considering 30-day quitting rather than not being still an established smoker at the time of interview, and that though the ORs are perhaps reduced slightly by restricting attention to those attempting to quit, they generally remain positive and in some analyses statistically significant.

The additional results show that cigarette smokers who also use smokeless tobacco or also use snus are also more likely to quit smoking, with some of the ORs for snus use larger than those for e-cigarettes. These results seem consistent with the general proposition that, even after detailed adjustment for potential confounding variables, those who both smoke and use a reduced risk tobacco product are more likely to quit smoking than those who do not also use the reduced risk product.

While it is clear that even more analyses could be run using the PATH study, the conclusions will inevitably be limited by sample size considerations, and a larger and well-designed study could provide a clearer picture. Further analyses could, for example, relate the probability of quitting to the extent of e-cigarette use, not considered in our analyses.

Two other analyses of e-cigarettes and quitting have been conducted based on Waves 1 to 4 of the PATH study.

In an analysis considering a variety of transitions in tobacco use between Waves, Brouwer et al. (2020) reported that cigarette smokers using e-cigarettes were more likely to quit cigarettes than were exclusive cigarette smokers (hazard ratio 1.9, 95%CI 1.6 to 2.3).
In contrast, Chen et al. (2020) concluded that “e-cigarettes may not be an effective cessation aid for adult smokers and instead may contribute to nicotine dependence”. They found that among smokers using e-cigarettes to help quit, rates of long-term abstinence were only 2% higher (95% CI −3% to 7%) than in matched smokers not using e-cigarettes, and also that fewer e-cigarette users were long-term abstinent from all nicotine products (Difference −4%, 95% CI −7% to −1%), though this second finding is not specifically related to quitting cigarette smoking.

Conclusion
Our results clearly suggest that among US adults aged 25 years or more, most of whom would not have initiated smoking recently, e-cigarettes may assist in helping smokers to quit, particularly if, at baseline, e-cigarettes form an important part of total tobacco use – i.e. for individuals who at baseline did not use products other than cigarettes or e-cigarettes, and who were current rather than ever e-cigarette users. These conclusions apply whether delayed, temporary or sustained quitting is considered. They are independent of the definition of quitting used, whether all cigarette smokers are considered or only those considering quitting. The results seem consistent with most of the evidence from clinical trials, other analyses of the PATH study, and other epidemiological studies, and seem likely to apply to other countries and time periods.

Data availability
Underlying data
National Addiction & HIV Data Archive Program: Population Assessment of Tobacco and Health (PATH) Study

References
Al-Delaimy WK, Myers MG, Leas EC, et al.: E-cigarette use in the past and quitting behavior in the future: a population-based study. Am J Public Health. 2015; 105(6): 1213–1219. Erratum appears in Am J Public Health. 2015; 105(9): e7. PubMed Abstract | Publisher Full Text | Free Full Text
Antwi GO, Rhodes Dl: Association between e-cigarette use and chronic obstructive pulmonary disease in non-asthmatic adults in the USA. J Public Health (Oxf). 2022; 44(1): 158–64. PubMed Abstract | Publisher Full Text
Baldassarri SR, Bernstein SL, Chupp GL, et al.: Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: A pilot study. Addict Behav. 2018; 80: 1–5. PubMed Abstract | Publisher Full Text | Free Full Text
Beard E, West R, Michie S, et al.: Association of prevalence of electronic cigarette use with smoking cessation and cigarette consumption in England: a time-series analysis between 2006 and 2017. Addiction. 2020; 115(5): 961–974. PubMed Abstract | Publisher Full Text | Free Full Text
Bennmarhnia T, Pierce JP, Leas E, et al.: Can e-cigarettes and pharmaceutical aids increase smoking cessation and reduce cigarette consumption? Findings from a nationally representative cohort of American smokers. Am J Epidemiol. 2018; 187(11): 2397–2404. PubMed Abstract | Publisher Full Text | Free Full Text
Berson G, Xie W, Harlow AF, et al.: E-Cigarette Use and Risk of Cardiovascular Disease: A Longitudinal Analysis of the PATH Study (2013-2019). Circulation. 2022; 145(20): 1557–9. PubMed Abstract | Publisher Full Text
Berry KM, Reynolds LM, Collins JM, et al.: E-cigarette initiation and associated changes in smoking cessation and reduction: the Population Assessment of Tobacco and Health Study, 2013-2015. Tob Control. 2019; 28(1): 42–49. PubMed Abstract | Publisher Full Text | Free Full Text
Bowler RP, Hansel NN, Jacobson S, et al.: Electronic cigarette use in US adults at risk for or with COPD: Analysis from two observational cohorts. J Gen Intern Med. 2017; 32(12): 1315–1322. PubMed Abstract | Publisher Full Text | Free Full Text
Brose LS, Hitchman SC, Brown J, et al.: Is the use of electronic cigarettes while smoking associated with smoking cessation attempts, cessation and reduced cigarette consumption? A survey with a 1-year follow-up. Addiction. 2015; 110(7): 1160–8. PubMed Abstract | Publisher Full Text | Free Full Text
Brouwer AF, Leon J, Hirschick Jl, et al.: Transitions between cigarette, ENDS and dual use in adults in the PATH study (waves 1-4): multistate transition modelling accounting for complex survey design. Tob Control. 2020; tobaccocontrol-2020-055967. PubMed Abstract | Publisher Full Text
Bullen C, Howe C, Laugesen M, et al.: Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013; 382(9905): 1629–37. PubMed Abstract | Publisher Full Text
Caponnetto P, Campagna D, Cibella F, et al.: Efficiency and safety of an eElectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomised control design study. PLoS One. 2014; 9(1): e86317. Erratum appears in PLoS One. 2014; 9(1): e86317. PLoS One. 2014; 9(1). doi: 10.1371/annotation/e12c22d3-a42b-455d-9100-6c7ee45d58d0. PubMed Abstract | Publisher Full Text | Free Full Text

The data are available under the Terms of Use as set out by ICPSR, which can be accessed when users start the process of downloading the data.

Extended data
Open Science Framework: Investigating the effect of e-cigarette use on quitting smoking in adults aged 25 or more using the PATH study https://doi.org/10.17605/OSF.IO/5XWQP (Lee et al., 2020).

This project contains the following extended data file:
- Additional file_fuller details regarding the predictor variables used_v2.docx

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

Acknowledgements
We thank Esther Afolalu for assistance in acquiring the data from the PATH study, and Zheng Sponsiello-Wang and Christelle Chrea for providing technical comments at various stages. We also thank Jan Hamling for assistance in running the analyses, and Yvonne Cooper and Diana Morris for typing various drafts of the paper.
in PATH wave 1 data. *Addiction.* 2020; 115(11): 2176–9. PubMed Abstract | Publisher Full Text

Snow E, Johnson T, Ossip Dj, et al.: Does e-cigarette use at baseline influence smoking cessation rates among 2-year college students? *Smok Cessat.* 2018; 13(2): 110–120. PubMed Abstract | Publisher Full Text | Free Full Text

Sweet L, Brasky TM, Cooper S, et al.: Quitting behaviors among dual cigarette and e-cigarette users and cigarette smokers enrolled in the tobacco user adult cohort. *Nicotine Tob Res.* 2019; 21(3): 278–284. PubMed Abstract | Publisher Full Text | Free Full Text

United States Department of Health and Human Services (USDHHS): Population assessment of tobacco and health (PATH) Study [United States] Public-Use Files (ICPSR 36498-V8). Accessed: 2018.

Reference Source

Verplaetse TL, Moore KE, Pittman BP, et al.: Intersection of e-cigarette use and gender on transitions in cigarette smoking status: Findings across Waves 1 and 2 of the Population Assessment of Tobacco and Health Study. *Nicotine Tob Res.* 2019; 21(10): 1423-1428. PubMed Abstract | Publisher Full Text | Free Full Text

Walker N, Parag V, Verbient M, et al.: Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. *Lancet Respir Med.* 2020; 8(1): 54–64. PubMed Abstract | Publisher Full Text

Wang MP, Li WH, Wu Y, et al.: Electronic cigarette use is not associated with quitting of conventional cigarettes in youth smokers. *Pediatr Res.* 2017; 82(1): 14-18. PubMed Abstract | Publisher Full Text

Watkins SL, Thrul J, Max W, et al.: Real-world effectiveness of smoking cessation strategies for young and older adults: Findings from a nationally representative cohort. *Nicotine Tob Res.* 2020; 22(9): 1560–1568. PubMed Abstract | Publisher Full Text | Free Full Text

Weaver SR, Huang J, Pechacek TF, et al.: Are electronic nicotine delivery systems helping cigarette smokers quit? Evidence from a prospective cohort study of U.S. adult smokers, 2015–2016. *PLoS One.* 2018; 13(7): e0198047. PubMed Abstract | Publisher Full Text | Free Full Text

West R, Bauld L, O'Connor R, et al.: Expert reaction to meta-analysis looking at e-cigarette use and smoking cessation. Accessed: 2016a March. Reference Source

West R, Shahab L, Brown J: Estimating the population impact of e-cigarettes on smoking cessation in England. *Addiction.* 2016b; 111(6): 1118–9. PubMed Abstract | Publisher Full Text

Wu SY, Wang MP, Li WH, et al.: Does electronic cigarette use predict abstinence from conventional cigarettes among smokers in Hong Kong? *Int J Environ Res Public Health.* 2018; 15(3): 400. PubMed Abstract | Publisher Full Text | Free Full Text

Young-Wolff KC, Klebaner D, Flock B, et al.: Documentation of e-cigarette use and associations with smoking from 2012 to 2015 in an integrated healthcare delivery system. *Prev Med.* 2018; 109: 113-118. PubMed Abstract | Publisher Full Text | Free Full Text

Zhang YY, Bu FL, Dong F, et al.: The effect of e-cigarettes on smoking cessation and cigarette smoking initiation: An evidence-based rapid review and meta-analysis. *Tob Induc Dis.* 2021; 19: 04. PubMed Abstract | Publisher Full Text | Free Full Text

Zhu SH, Zhuang YL, Wong S, et al.: E-cigarette use and associated changes in population smoking cessation: evidence from US current population surveys. *BMJ.* 2017; 358: j3262. PubMed Abstract | Publisher Full Text | Free Full Text

Zhuang YL, Cummins SE, Sun IY, et al.: Long-term e-cigarette use and smoking cessation: a longitudinal study with US population. *Tob Control.* 2016; 25(Suppl 1): i90–i95. PubMed Abstract | Publisher Full Text | Free Full Text
The authors disagree with all of our points without refutation and have announced their intention not to revise in response to our concerns. This includes our concerns on two critical scientific methods issues: 1) by not restricting the study population to those who had made a quit attempt, the study is tainted by reverse causation and 2) that the variable selection strategy employed opens the study to major collider bias. Our prior evaluation stands. This paper cannot be approved.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** 1. John Pierce, behavioral epidemiology with an emphasis on tobacco use 2. Tarik Benmarhnia, epidemiological methods 3. Karen Messer, statistical methods

We confirm that we have read this submission and believe that we have an appropriate level of expertise to state that we do not consider it to be of an acceptable scientific standard, for reasons outlined above.
Riccardo Polosa

Center of Excellence for the Acceleration of HArm Reduction (CoEHAR), Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

I have reviewed this new version. Revisions are appropriate and I have no additional comments.

Competing Interests: RP is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. In relation to his recent work in the area of respiratory diseases, clinical immunology, and tobacco control, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. Lecture fees from a number of European EC industry and trade associations (including FIVAPE in France and FIESEL in Italy) were directly donated to vaper advocacy nonprofit organizations. RP has also received grants from European Commission initiatives (U-BIOPRED and AIRPROM) and from the Integral Rheumatology & Immunology Specialists Net-work (IRIS) initiative. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, Boehringer Ingelheim, Novartis, Duska Therapeutics, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., Health Diplomats, and Sermo Inc. RP has served on the Medical and Scientific Advisory Board of Cordex Pharma, Inc., CV Therapeutics, Duska Therapeutics Inc, Pfizer, and PharmaCielo. RP is also founder of the Center for Tobacco prevention and treatment (CPCT) at the University of Catania and of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR) at the same University, which has received support from Foundation for a Smoke Free World to conduct 8 independent investigator-initiated research projects on harm reduction. RP currently involved in a patent application concerning an app tracker for smoking behaviour developed for ECLAT Srl. RP is also currently involved in the following pro bono activities: scientific advisor for LIAR, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League), the Consumer Advocates for Smoke-free Alternatives (CASAA) and the International Network of Nicotine Consumers Organizations (INNCO); Chair of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). I confirm that these potential conflicts of interest did not affect my ability to write an objective and unbiased review of the article.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
© 2022 Selya A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✅ Arielle S. Selya
PinneyAssociates, Inc., Pittsburgh, PA, USA

No further comments.

**Competing Interests:** I am an employee of PinneyAssociates, Inc., which provides consulting services on tobacco harm reduction on an exclusive basis to JUUL Labs, Inc. JUUL had no role in this review. I confirm that this potential conflict of interest did not affect my ability to write an objective and unbiased review of the article.

**Reviewer Expertise:** Tobacco use behavior

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 21 June 2022
https://doi.org/10.5256/f1000research.135096.r141343

© 2022 Kaplan A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✅ Alan G. Kaplan
Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada

The authors did respond to my responses, other than making it more clinical which they recognized was not in their domain.

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 2
Reviewer Report 20 May 2022
https://doi.org/10.5256/f1000research.54961.r134820
Arielle S. Selya
Pinney Associates, Inc., Pittsburgh, PA, USA

This manuscript examines the association between e-cigarette use and subsequently discontinuing smoking, using PATH data from adults 25+. E-cigarette use is associated with discontinuing smoking after adjusting for a wide range of covariates, and this association is robust across an impressive range of sensitivity analyses (e.g. omitting users of other tobacco products; using several different outcome measures, including sustained, delayed, and temporary discontinuing smoking; restricting analyses to those who made a quit attempt). While (as the authors note) there have been several similar studies on this question using PATH, a particular advantage of this one in my judgment is including those smokers who did not make a quit attempt (thus capturing some of the accidental switching phenomenon that seems to make e-cigarettes so effective). Another advantage is including former smokers in the analysis, as that captures more people who already successfully switched between waves, as opposed to other studies which subset to who's still smoking at the time of data collection.

Major comments:
  ○ Consider changing “quitting” to “discontinuation of smoking” throughout. The word “quitting” has connotations of formal smoking cessation, which involves explicitly setting quit goals, taking certain actions for the purpose of quitting, etc. However, as the authors point out, this does not apply to the entire sample: most smokers at any given time are not immediately planning to quit, if ever. For this reason, the PATH team has used the term “discontinuation of smoking” to make this distinction (see Kasza et al., 2021). Using this terminology rather than “quitting” may also help to clarify some of the criticisms to the V1 of this manuscript and the Glasser study (i.e. whether those who made no attempt to quit should be included).

  ○ Is it the case that successful switchers between waves were included in the analysis? I believe this is the case based on including both former and current smokers. If so, that is a great strength of this paper compared to most others (which usually focus only on those who remain current smokers, and thus exclude those who successfully switched to e-cigarettes between waves), and is worth explicitly pointing out.

Minor comments:
  ○ Missing word (?) in Abstract, 1st sentence of Results (“ORs of quitting smoking forever e-cigarette use were...”).

  ○ The tables which present ORs could present significant ones (not crossing 1) as boldface for easier presentation of the many results.

References
1. Kasza K, Edwards K, Kimmel H, Anesetti-Rothermel A, et al.: Association of e-Cigarette Use With Discontinuation of Cigarette Smoking Among Adult Smokers Who Were Initially Never Planning to
Quit. *JAMA Network Open*. 2021; 4 (12). Publisher Full Text

*Is the work clearly and accurately presented and does it cite the current literature?*

Yes

*Is the study design appropriate and is the work technically sound?*

Yes

*Are sufficient details of methods and analysis provided to allow replication by others?*

Yes

*If applicable, is the statistical analysis and its interpretation appropriate?*

Yes

*Are all the source data underlying the results available to ensure full reproducibility?*

Yes

*Are the conclusions drawn adequately supported by the results?*

Yes

**Competing Interests:** I am an employee of PinneyAssociates, Inc., which provides consulting services on tobacco harm reduction on an exclusive basis to JUUL Labs, Inc. JUUL had no role in this review. I confirm that this potential conflict of interest did not affect my ability to write an objective and unbiased review of the article.

**Reviewer Expertise:** Tobacco use behavior

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 Jun 2022

**Peter Lee,** P.N.Lee Statistics and Computing, Sutton, UK

We thank Dr Selya for her comments.

As regards the first major comment of Dr. Selya, we have not changed “quitting” to “discontinuation of smoking” throughout, as we have already published a very large number of papers using quitting in the sense that we do, and one that is widely understood by epidemiologists. However we have added an extra paragraph (2) in the discussion which explains our terminology. Thus the paragraph starts:

**Note that the term “quitters”, as used here, relates to those who were smoking at baseline, but not at the end of follow-up, even though they may later relapse to smoking. Some prefer the term “discontinuation of cigarette smoking”, the paragraph then going on to cite the reference to Kasza et al., 2021 that Dr. Selya mentioned.**
The same paragraph answers the second major comment of Dr. Selya regarding the inclusion of switchers in the analysis. Thus, the paragraph goes on to state:

Here, we use “quitting” to relate to cigarette smoking, regardless of use of, or switching to, e-cigarettes or other nicotine products,

the paragraph then going on to point out that we use “smoking”, not further defined, to relate to cigarettes.

Finally the minor comments have been dealt with by:
1) Correcting the typo of forever to for ever and;
2) Making significant ORs in boldface in Tables 2, 3, 4, 6 and 7 with a note in the text about this when introducing Table 2.

We hope that our paper can now be approved.

**Competing Interests:** We are long term consultants to the tobacco industry

---

**Reviewer Report 14 January 2022**

https://doi.org/10.5256/f1000research.54961.r119744

© 2022 Kaplan A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alan G. Kaplan  
Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada

This study was to review from another larger trial regarding factors to affect smoking cessation that looked at e-cigarette efficacy in such.

I found this to be a very difficult study to read, very statistical, which is fine, but not very clinical. You discuss multiple waves, but I am not sure how relevant these are with regards to e-cigarettes and cessation.

The findings are very important to reinforce the potential value of e-cigarettes for smoking cessation, but there is no balance regarding the potential adverse effects of e-cigarettes which are a concern for many physicians.

While multiple parameters are reviewed as possible confounders, other pharmacotherapeutic smoking cessation options are not included.

**Is the work clearly and accurately presented and does it cite the current literature?**  
Yes
Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Respiratory illness and chronic pain

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 Jun 2022

Peter Lee, P.N.Lee Statistics and Computing, Sutton, UK

We thank Dr. Kaplan for his comments.

As regards the comment “I found it to be a very difficult study to read, very statistical, which is fine, but not very clinical” all we can say is that neither of the authors are medically qualified, and both are statisticians, and as there were a large number of analyses to describe, the paper was inevitably rather statistical.

Dr. Kaplan also says “You discuss multiple waves, but I am not sure how relevant these are with regards to e-cigarettes and cessation.” Clearly, when studying cessation one needs data at two time points (waves), to have individuals changing from being smokers to non-smokers, i.e. quitting. Our original analyses carried out data for Waves 1 to 3, Waves 1 to 2, and Waves 2 to 3, partly to see how consistent our findings were over the different periods considered. Our later analyses used Wave 4 as well to allow us to study in detail sustained, delayed and temporary quitting, and to test consistency of our results for different periods (Waves 1 to 3, 2 to 4, and 1 to 4). Note that you need data from at least three time points to study these forms of quitting. Thus sustained quitting is YNN, delayed quitting is YYN- and temporary quitting is YNY, where Y (yes) indicates smoking and N (no) indicates not smoking.

Dr. Kaplan says that there is no balance regarding the potential adverse effects of e-
cigarettes which are a concern for many physicians. In response to this we would point out that the introduction to the paper did already mention in general terms the various possible upsides and downsides of e-cigarettes. However, we have slightly extended the initial sentence to mention some of the evidence supporting the view that any effects of e-cigarettes on health are substantially less than those of smoking. As the paper is specifically about the relationship of e-cigarette use to quitting cigarettes, we would rather not, in a paper that is already rather long, to attempt to summarize all the evidence relating to health effects, let alone the other areas that we refer to in the first paragraph, such as on initiation and cigarette consumption.

The final point of Dr. Kaplan was that we did not consider pharmacotherapeutic smoking cessation options other than e-cigarettes as possible confounders. However, we did consider them – please see the inclusion of “Ever used Chantix, varenicline or buproprion (Wellbutrin, Zyban)” in Tables 1 and 3.

We hope that our paper can now be approved.

**Competing Interests:** We are long term consultants to the tobacco industry
smoking is less likely to quit over a given period than people who still smoke but have never tried e-cigarettes. This is what happens when you remove most success stories from the study population. Moreover, it can be speculated that many of those who were inclined to switch to vaping would have already done so prior to enrollment, creating a stock-flow bias. These possibilities should be discussed in the text.

At the individual level, the counterfactual of primary interest is whether someone successfully quits smoking because vaping exists, when either they would have failed to quit as they did without the aid of vaping or never would have even made the attempt but for trying vaping. I am not sure this has been addressed in the paper – e.g. by comparing at-risk people (people who smoke, and thus are at-risk for quitting) who have the exposure (which might be defined as trying vaping or some greater level of usage) to those who do not, trying to control for confounding.

Details of vaping behavior (e.g. daily use at follow-up) may be important predictors of elevated quit rates. Those who vaped daily may considerably more likely to be smoking abstinent than average, while those who used them less-than-daily were a bit less likely. It would be interesting to stratify the analysis separating daily vs occasional (i.e. less-than-daily) e-cigarette use at follow up to see if there is a “dose/exposure-related” effect on the observed quit rates.

The most compelling evidence that vaping causes some smoking cessation, though it does not allow for quantification, is the countless individual testimonials of quitting with vaping, including many accidental quitter stories and stories of having abandoned hope of quitting until vaping became an option. This evidence should be addressed, even as background.

Some important papers are not cited here, e.g. Gomajee et al., 2019, in which the authors looked at a large (the data included over 5000 people who smoke and 2000 who did formerly) nationally representative cohort in France, with recruitment starting in 2012 and following participants for an average of two years at the time their results were reported. Data was collected on not just recent e-cigarette use but also on when someone started vaping regularly, a simple useful question that is woefully missing from most studies.

The possibility of self-selection bias for the PATH study must be acknowledged in the text.

To the authors’ credit, they do not delve into offhand speculation about policy implications or statements of personal opinions, and are refreshingly epistemically modest. However, they should discuss how their time- and country-specific behavioral data might or might not generalize outside US, and suggest potential implications of their findings.

Is the work clearly and accurately presented and does it cite the current literature?  
Yes

Is the study design appropriate and is the work technically sound?  
Yes

Are sufficient details of methods and analysis provided to allow replication by others?  
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.

**Are all the source data underlying the results available to ensure full reproducibility?**  
Yes

**Are the conclusions drawn adequately supported by the results?**  
Yes

**Competing Interests:** RP is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. In relation to his recent work in the area of respiratory diseases, clinical immunology, and tobacco control, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. Lecture fees from a number of European EC industry and trade associations (including FIVA PE in France and FIESEL in Italy) were directly donated to vaper advocacy nonprofit organizations. RP has also received grants from European Commission initiatives (U-BIOPRED and AIRPROM) and from the Integral Rheumatology & Immunology Specialists Net-work (IRIS) initiative. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, Boehringer Ingelheim, Novartis, Duska Therapeutics, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., Health Diplomats, and Sermo Inc. RP has served on the Medical and Scientific Advisory Board of Cordex Pharma, Inc., CV Therapeutics, Duska Therapeutics Inc, Pfizer, and PharmaCielo. RP is also founder of the Center for Tobacco prevention and treatment (CPCT) at the University of Catania and of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR) at the same University, which has received support from Foundation for a Smoke Free World to conduct 8 independent investigator-initiated research projects on harm reduction. RP currently involved in a patent application concerning an app tracker for smoking behaviour developed for ECLAT Srl. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian ac-ronym for Italian Anti-Smoking League), the Consumer Advocates for Smoke-free Alternatives (CASAA) and the International Network of Nicotine Consumers Organizations (INNCO); Chair of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). I confirm that these potential conflicts of interest did not affect my ability to write an objective and unbiased review of the article.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

**Author Response 10 Jun 2022**

**Peter Lee**, P.N.Lee Statistics and Computing, Sutton, UK

We thank Dr. Polosa for his comments.
Dr. Polosa notes that we should reassure readers that our multivariate models include variables sufficient to calculate propensity to start or quit smoking.

We note that our original discussion section already included a paragraph starting “The strengths of our work...” which included, as one of the strengths “analyses which take account of a very large numbers of other predictors of quitting”. We did not consider propensity to start smoking, as the paper was about quitting. Though, of course, there might be some lurking relevant variable ignored, the list of predictors of quitting considered in our Table1 included as many as 55 variables.

In his next paragraph, Dr. Polosa asks that we make clear if the population of current smokers at baseline excludes those previously trying and failing e-cigarettes prior to enrolment.

In response to this we note that the fourth paragraph of the methods section defines what is meant by a current, former, or ever e-cigarette user, and that while our main model (results shown in Tables 2 and 3) relate to the relationship of quitting to ever e-cigarette use at baseline, sensitivity analysis 2 (results shown in Table 4) relate quitting to current e-cigarette use at baseline. Although there may be reasons, as Dr. Polosa states, why restricting attention to current e-cigarette users at baseline might show a stronger relationship, in practice there was no significant difference between the odds ratios for the main model and sensitivity analysis 2, both showing a positive relationship between e-cigarette use and quitting, as mentioned near the end of the first paragraph of the discussion.

In the following paragraph (starting “At the individual level...”) Dr. Polosa states that we might compare quitting rates in people who smoke who have the exposure (e-cigarettes) and who do not have it, trying to control for confounding. But that is exactly what we have done – for example in Table 3, the odds ratio for “ever regularly used e-cigarette = yes” are based on a comparison with “ever regularly used e-cigarette = no” and are adjusted for the confounders described.

In the next paragraph (starting “Details of vaping behavior...”) Dr. Polosa suggests that dose-response analyses relating quit rates to “dose” of e-cigarette use would be of interest. We agree, but given the extent of the analyses already presented, and the fact that new waves of PHIM are by now available, we would prefer to carry out such analyses for a possible later publication. The possibility of this is now mentioned in the discussion in the paragraph starting “While it is clear that even more analyses could be run...”, where we have added the extra sentence “Further analyses could, for example, relate the probability of quitting to the extent of e-cigarette use, not considered in our analyses.”

The following paragraph (starting “The most compelling evidence...”) refers to “countless individual testimonials of quitting with vaping...”. Without any reliable reference to this, we would not be able to say anything scientifically useful. We wonder whether those who try vaping to quit and find it didn't help report this as often as those who find it did work. Given the PATH study has no data here, we prefer not to go down this path.

Next, Dr. Polosa refers to some important papers not cited here, mentioning the paper by Gomajee et al., 2019. We have now included that paper in the reference list supporting the
statement that “it is clear that by now there are quite a number of studies which report somewhat higher quit rates in those using e-cigarettes” in the fourth paragraph of the introduction. However, please note that that list and the one following it are only a selection of papers finding or not finding a clear association, as noted by the “e.g.” at the beginning of each list.

As regards raising the possibility of self-selection bias for the PATH study, we have modified the start of the paragraph in the discussion to read “The strengths of our work include the use of a prospective study design based on a study population which is reasonably representative of the US (though subject to some selection bias)...”.

Finally, Dr. Polosa suggests that we discuss how our results might generalize outside the US. Here, without going into a detailed discussion covering all the major e-cigarette-using countries other than the US, we have just extended the conclusions section so that the final sentence now reads “The results seem consistent with most of the evidence from clinical trials, other analyses of the PATH study, and other epidemiological studies, and seem likely to apply to other countries and time periods.”

We hope that our paper can now be approved.

**Competing Interests:** We are long term consultants to the tobacco industry
Reviewer 2nd response:
The National Academies of Science Engineering and Medicine\(^1\) highlighted that the research addressed at least two different research questions. The first was that e-cigarettes with nicotine were more effective than e-cigarettes without nicotine in medium term abstinence after a quit attempt. The second is the effectiveness of e-cigarettes as cessation aids compared to any other method. It is this question that is the focus of this paper and the NASEM report noted that, as of 2018, RCT’s had not really addressed this question.

The authors now reference 10 randomized trials (RCTs) most of which do not address the research question that they are addressing in this paper.

Further, there are a number of different “systematic” reviews of this literature and they differ widely in their conclusions. Rather than present both sides, the authors “cherry-pick” from these reviews to support their hypothesis.

- Previous comment on the importance of limiting consideration to people who had made a quit attempt. This previous comment noted that the likelihood of a quit attempt was much higher in e-cigarette users in the PATH study (many who started using e-cigarettes did so because they were trying to quit) than it was in the control population. Thus, the higher probability of making a quit attempt could explain the difference in smoking cessation and so the difference should not be attributed to the use of e-cigarettes.

Authors’ response - they have adjusted for quitting in some analyses but “We did not say that the population needed to have made a recent quit attempt, as this was not a requirement in our study. Our analyses compared quit rates between e-cigarette users and non-users to try to answer the simpler, and highly relevant, question ‘are e-cigarette users more likely to quit?’

Reviewer 2nd response: Furthering our previous comment, there now are multiple publications demonstrating that e-cigarettes are the most popular choice for smokers looking for help during a quit attempt. In other words, those who make quit attempt are more likely to use e-cigarettes than those who don't make quit attempt, thus, to answer the authors “simpler” question - of course e-cigarette users are more likely to quit, because the reason they are using an e-cigarette is to help them quit. More generally speaking, this is an example of Simpson's paradox. The effects of e-cigarette use are totally different among those who make quit attempt and those who don't. The importance of not making this error in analyzing cohort studies was not originally brought up by our team. Rather, it was a warning included in the National Academies of Science, Engineering and Medicine 2018 report on e-cigarettes.

We noticed that the authors have made a minimum attempt to adjust for this confounder variable by using “Have tried to quit completely”. This is not sufficient to address the problem. Firstly, the interaction between e-cigarette use and the quit attempts has been shown to be important in previous studies (those focused on recent quit attempters). Second, the variable “Have tried to quit completely” is not qualified by time in any way. Thus, the attempt to quit completely may have happened in the past year but the use of e-cigarettes may have happened before then. Thus, the exposure might have happened before the assessment of the confounder, a classical error for anyone studying an etiological problem. By refusing to separate their consideration to smokers who had made a quit attempt and who hadn't, the authors have introduced a substantial bias into their analysis that invalidates their findings.

- Is it appropriate to use an analytic strategy based on stepwise regressions to select model covariates that are then use to infer causal relationships between e-cigarettes and quitting outcomes.

The authors main research question of interest is etiological (as opposed to one that seeks simply to describe the data or to address a predictive research questions (see Hernán 2018, Hernán, Hsu
et al. 2019)\textsuperscript{2,3}. For an etiological question, the identification and conditioning on potential confounders is crucial. For such questions, selecting potential confounders in an outcome model (like a multivariable model) based on statistical criteria has been repeatedly shown to be erroneous (Greenland \textsuperscript{1989}, Smith \textsuperscript{2018})\textsuperscript{4,5} especially when covariates induced by the exposure and the outcome are included which may lead to collider-stratification bias. Therefore, the entire analytical plan has to be revisited as all effect estimates presented are based on an erroneous analytical approach and none of the ORs can be used to infer any relationship between e-cigarette use and cigarettes quitting.

References
1. Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems, Board on Population Health and Public Health Practice, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine: Public Health Consequences of E-Cigarettes. 2018. Publisher Full Text
2. Hernán MA: The C-Word: Scientific Euphemisms Do Not Improve Causal Inference From Observational Data. \textit{Am J Public Health}. 108 (5): 616-619 PubMed Abstract | Publisher Full Text
3. Hernán M, Hsu J, Healy B: A Second Chance to Get Causal Inference Right: A Classification of Data Science Tasks. \textit{CHANCE}. 2019; 32 (1): 42-49 Publisher Full Text
4. Greenland S: Modeling and variable selection in epidemiologic analysis. \textit{Am J Public Health}. 1989; 79 (3): 340-9 PubMed Abstract | Publisher Full Text
5. Smith G: Step away from stepwise. \textit{Journal of Big Data}. 2018; 5 (1). Publisher Full Text

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

\textit{Competing Interests}: No competing interests were disclosed.

\textit{Reviewer Expertise}: Behavioral Epidemiology, with a major focus on tobacco use behavior.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to state that we do not consider it to be of an acceptable scientific standard, for reasons outlined above.
Author Response 08 Apr 2021

Peter Lee, P.N.Lee Statistics and Computing, Sutton, UK

We thank Drs Chen and Pierce for their second set of comments. Our replies, disagreeing with virtually all the points they make, are given below italics. We do not intend to revise our paper further based on this second set of comments.

Not Approved
This paper has been rewritten to address concerns that were expressed with the initial version.

○ Previous comment: The introduction presents a somewhat limited review of the literature.

Authors’ Response: dismissed this comment, asserting that their presentation was a relatively succinct summary of the findings in the literature.

Reviewer 2nd response:
The National Academies of Science Engineering and Medicine highlighted that the research addressed at least two different research questions. The first was that e-cigarettes with nicotine were more effective than e-cigarettes without nicotine in medium term abstinence after a quit attempt.

This first question is not particularly relevant to our paper, which is concerned with comparing quit rates in e-cigarette users as a whole versus non-users of e-cigarettes.

The second is the effectiveness of e-cigarettes as cessation aids compared to any other method. It is this question that is the focus of this paper

We don't understand why Drs Chen and Pierce think we were attempting to answer this second question? We weren't.

and the NASEM report noted that, as of 2018, RCT's had not really addressed this question

The authors now reference 10 randomized trials (RCTs) most of which do not address the research question that they are addressing in this paper.

Further, there are a number of different “systematic” reviews of this literature and they differ widely in their conclusions. Rather than present both sides, the authors “cherry-pick” from these reviews to support their hypothesis.

Drs Chen and Pierce are commenting on the paragraph in the introduction of our paper concerning randomized controlled trials. This was intended to give some context to our paper, though of course our main analyses concern evidence from a non-randomized epidemiological study. we had cited three references as suggesting that the evidence from randomized controlled trials was consistent with higher quit rates in those using e-cigarettes, one of these being a recent prestigious cochrans report. While we had selected these three major reviews based on a look at the recent literature, there was certainly no intention to “cherry-pick”, as we are accused of. Looking back at the reviews currently available, we could cite other reviews that consider that the evidence suggests (as it does) higher quit rates in e-cigarette users, but none that it suggest lower quit rates. We consider our paragraph to be a fair reflection of the evidence from rcts.
Previous comment on the importance of limiting consideration to people who had made a quit attempt. This previous comment noted that the likelihood of a quit attempt was much higher in e-cigarette users in the PATH study (many who started using e-cigarettes did so because they were trying to quit) than it was in the control population. Thus, the higher probability of making a quit attempt could explain the difference in smoking cessation and so the difference should not be attributed to the use of e-cigarettes.

**Authors’ response** - they have adjusted for quitting in some analyses but “We did not say that the population needed to have made a recent quit attempt, as this was not a requirement in our study. Our analyses compared quit rates between e-cigarette users and non-users to try to answer the simpler, and highly relevant, question ‘are e-cigarette users more likely to quit?’

**Reviewer 2nd response:** Furthering our previous comment, there now are multiple publications demonstrating that e-cigarettes are the most popular choice for smokers looking for help during a quit attempt. In other words, those who make quit attempt are more likely to use e-cigarettes than those who don't make quit attempt, thus, to answer the authors “simpler” question - of course e-cigarette users are more likely to quit, because the reason they are using an e-cigarette is to help them quit. More generally speaking, this is an example of Simpson's paradox. The effects of e-cigarette use are totally different among those who make quit attempt and those who don't. The importance of not making this error in analyzing cohort studies was not originally brought up by our team. Rather, it was a warning included in the National Academies of Science, Engineering and Medicine 2018 report on e-cigarettes.

We noticed that the authors have made a minimum attempt to adjust for this confounder variable by using “Have tried to quit completely”. This is not sufficient to address the problem. Firstly, the interaction between e-cigarette use and the quit attempts has been shown to be important in previous studies (those focused on recent quit attempters). Second, the variable “Have tried to quit completely” is not qualified by time in any way. Thus, the attempt to quit completely may have happened in the past year but the use of e-cigarettes may have happened before then. Thus, the exposure might have happened before the assessment of the confounder, a classical error for anyone studying an etiological problem. By refusing to separate their consideration to smokers who had made a quit attempt and who hadn't, the authors have introduced a substantial bias into their analysis that invalidates their findings.

In using the word “refusing” in their final sentence, Chen and Pierce seem to have missed completely the highly relevant fact that in our analyses based on waves 1 to 4 we included a sensitivity analysis 6 excluding those not attempting to quit, and that for sustained quitting (perhaps the most relevant measure) the associations were weaker if anything than those seen in the main analysis, indicating that increased quitting rates were seen also in those not attempting to quit.

**Is it appropriate to use an analytic strategy based on stepwise regressions to select model covariates that are then use to infer causal relationships between e-cigarettes and quitting outcomes.**

The authors main research question of interest is etiological (as opposed to one that seeks simply to describe the data or to address a predictive research questions (see Hernán 2018, Hernán, Hsu et al. 2019). For an etiological question, the identification and conditioning
on potential confounders is crucial. For such questions, selecting potential confounders in an outcome model (like a multivariable model) based on statistical criteria has been repeatedly shown to be erroneous (Greenland 1989, Smith 2018)\textsuperscript{4,5} especially when covariates induced by the exposure and the outcome are included which may lead to collider-stratification bias. Therefore, the entire analytical plan has to be revisited as all effect estimates presented are based on an erroneous analytical approach and none of the ORs can be used to infer any relationship between e-cigarette use and cigarettes quitting.

While we agree that in principle one shouldn’t adjust for variables induced by the exposure and the outcome, I do not believe that we had done so here. The variables we adjusted for were generally characteristics that were present before take up of e-cig use and before quitting, and therefore would not cause problems with over-correction.

References
1. Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems, Board on Population Health and Public Health Practice, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine: Public Health Consequences of E-Cigarettes. 2018. Publisher Full Text
2. Hernán MA: The C-Word: Scientific Euphemisms Do Not Improve Causal Inference From Observational Data.\textit{Am J Public Health}. 108 (5): 616-619 PubMed Abstract | Publisher Full Text
3. Hernán M, Hsu J, Healy B: A Second Chance to Get Causal Inference Right: A Classification of Data Science Tasks. \textit{CHANCE}. 2019; 32 (1): 42-49 Publisher Full Text
4. Greenland S: Modeling and variable selection in epidemiologic analysis.\textit{Am J Public Health}. 1989; 79 (3): 340-9 PubMed Abstract | Publisher Full Text
5. Smith G: Step away from stepwise. \textit{Journal of Big Data}. 2018; 5 (1). Publisher Full Text

Competing Interests: As noted in the paper, we are long term consultants to the tobacco industry.
Division of Biostatistics, University of California, San Diego, San Diego, CA, USA

John P. Pierce

Moores Cancer Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, San Diego, CA, USA

In the background of the abstract, the authors state that their goal is to address the research question whether e-cigarettes encourage smokers to quit using a quality nationally representative cohort study from the United States.

The introduction presents a somewhat limited review of the literature. In the discussion of the randomized trials the authors infer that these trials reached statistically significant findings where e-cigarettes were favored. This is a misrepresentation of the literature.

The authors note the following problems that have been identified with observational studies addressing the target research question: studies in which the exposure measure does not precede the outcome measure (as happens in cross-sectional studies), the use of non-representative populations, and failure to fully account for the many potential confounding factors. While these are appropriate criticisms of some of the literature, they are far from complete. For example, in 2018, the US National Academies of Science, Engineering and Medicine put out a major report on e-cigarettes where they expressed concern about the quality of some of the papers addressing whether these products were cessation aids: In addition to these three concerns, this report noted the importance of the study focusing on quit attempts with a comparable control group – this issue has been highlighted in the 2019 paper by Pierce et al. in Nicotine and Tobacco Research. This analysis showed that the likelihood of a quit attempt was much higher in e-cigarette users in the PATH study (many who started using e-cigarettes did so because they were trying to quit) than in was in the control population. Thus, the higher probability of making a quit attempt could explain the difference in smoking cessation and so the difference should not be attributed to the use of e-cigarettes.

However, the authors go further and argue “Problems involve the...failure to limit attention to established e-cigarette users,” (Para 4 introduction). It is not clear what the authors mean by this? Do they mean that the study population need to have developed a consistent pattern of dual use of cigarettes and e-cigarettes? What is their justification for such a limitation when addressing the stated research question? It is apparent that they do not place such a limitation on their own analyses.

Indeed, the authors have not laid out specific research questions or hypotheses that guide the analyses that they undertake in this paper. This is an important omission.

In the methods, the authors state that analyses are based on individuals with relevant data available at Waves 1, 2 and 3 on smoking and e-cigarette use. They do not mention that the population needed to have made a recent quit attempt. As noted above, unless they demonstrate that the populations that they choose are comparable on this variable, then their study is confounded.

The methods are not at all clear about the outcome measure used in this analysis. In their section outlining their main analyses, the authors use the term “quitting during follow-up”. What does this
mean? A logical interpretation is that a quit attempt was made in the year prior to the follow-up survey. However, the authors have not addressed the quit attempt data in the methods. Do they use a point prevalence of former smoking at the follow-up survey? If so, how can this be described as successful smoking cessation? This is one of the most critical points in the paper. Most other papers discussing successful quitting require abstinence for either 6 of 12 months at follow-up (see, Gilpin et al. 1997\(^2\)). This is particularly important in an observational study when a person quit at follow-up could have quit only for the day before the survey, for example.

The potential confounders in this analysis include those variables that are associated with use of e-cigarettes as well as variables that are associated with successful cessation. The authors omit any discussion of variables associated with the probability of a smoker using an e-cigarette, thus seriously confounding their analyses. At least in a supplement, there should be a summary table of these predictors outlining how they are associated with e-cigarette use.

Analytic Plan: The analysis plan lays out a stepwise forward selection logistic regression, adjusted for selected covariates. What is unclear is how the authors use step 5 & 6 of their analytic plan in drawing their inferences.

There is a problem with the use of study weights. For their Wave 2 to Wave 3 analysis, it would seem that the appropriate weights would be the Wave 2 weights.

A figure laying out the different analyses with samples sizes (including loss to follow-up) would be very helpful to the reader.

Results: The unadjusted quitting rates by ever use of e-cigarettes should be presented in a table in the results section.

Also, the authors should report the percentage of subjects excluded in the multiple regressions.

Any reworking of this manuscript should discuss the four recent analyses that address e-cigarettes and smoking using the PATH data. All these papers use appropriate analytic procedures and arrive at opposite conclusions to those of the authors\(^3\)\(^-\)\(^6\).

References
1. Pierce J, Messer K, Leas E, Kealey S, et al.: A Source of Bias in Studies of E-Cigarettes and Smoking Cessation. *Nicotine & Tobacco Research*. 2020; 22 (5): 861-862 Publisher Full Text
2. Gilpin EA, Pierce JP, Farkas AJ: Duration of smoking abstinence and success in quitting. *J Natl Cancer Inst*. 1997; 89 (8): 572-6 PubMed Abstract | Publisher Full Text
3. Pierce JP, Benmarhnia T, Chen R, White M, et al.: Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16.*PLoS One*. 2020; 15 (9): e0237938 PubMed Abstract | Publisher Full Text
4. Chen R, Pierce JP, Leas EC, White MM, et al.: E-Cigarette Use to Aid Long-Term Smoking Cessation in the US: Prospective Evidence from the PATH Cohort Study.*Am J Epidemiol*. 2020. PubMed Abstract | Publisher Full Text
5. Dai H, Leventhal A: Association of electronic cigarette vaping and subsequent smoking relapse among former smokers. *Drug and Alcohol Dependence*. 2019; 199: 10-17 Publisher Full Text
6. Everard CD, Silveira ML, Kimmel HL, Marshall D, et al.: Association of Electronic Nicotine Delivery System Use With Cigarette Smoking Relapse Among Former Smokers in the United States.*JAMA*
Is the work clearly and accurately presented and does it cite the current literature? 
Partly

Is the study design appropriate and is the work technically sound? 
No

Are sufficient details of methods and analysis provided to allow replication by others? 
Yes

If applicable, is the statistical analysis and its interpretation appropriate? 
Partly

Are all the source data underlying the results available to ensure full reproducibility? 
Yes

Are the conclusions drawn adequately supported by the results? 
No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Behavioral Epidemiology, with a major focus on tobacco use behavior.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to state that we do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 02 Oct 2020

Peter Lee, P.N.Lee Statistics and Computing, Sutton, UK

We thank the reviewers for their comments which we attempt to answer in detail below. Please note that, as advised by the journal, our proposed changes to the paper have not, at this stage, been made, pending comments from other reviewers on our paper. Please also note that, as explained in more detail below, some of the points raised by the reviewers will be dealt with more fully in a further paper we are currently preparing based on data from Waves 1 to 4, as mentioned in the penultimate paragraph of the conclusions section. As will be evident, the reviewers original comments are in normal type and our replies and suggested changes to the paper are in bold. We hope that our reply and the changes will affect the reviewers' opinion of our work.

In the background of the abstract, the authors state that their goal is to address the research question whether e-cigarettes encourage smokers to quit using a quality nationally representative cohort study from the United States.
The introduction presents a somewhat limited review of the literature.

The introduction was never intended to be a fully detailed and comprehensive review of the extensive literature relating e-cigarettes to quitting, the main purpose of the paper being to describe the results of our own analyses. Nevertheless the introduction includes as many as 39 references, and we feel gives a relatively succinct summary of the findings from the literature available at the time of writing.

In the discussion of the randomized trials the authors infer that these trials reached statistically significant findings where e-cigarettes were favored. This is a misrepresentation of the literature.

We made no reference to statistical significance and had not intended to imply this. We were merely summarizing the direction of the differences reported in the papers cited, virtually all of which indicated a higher quit rate in the nicotine e-cigarette group. However to avoid confusion, the second sentence of the second paragraph of the discussion will be amended so that it ends

‘...generally indicates higher quit rates in the nicotine e-cigarette group, although not all the differences cited were statistically significant (at p<0.05), and one study did not find such higher quit rates (Halpern et al., 2018).’

The authors note the following problems that have been identified with observational studies addressing the target research question: studies in which the exposure measure does not precede the outcome measure (as happens in cross-sectional studies), the use of non-representative populations, and failure to fully account for the many potential confounding factors. While these are appropriate criticisms of some of the literature, they are far from complete. For example, in 2018, the US National Academies of Science, Engineering and Medicine put out a major report on e-cigarettes where they expressed concern about the quality of some of the papers addressing whether these products were cessation aids:

We had already stated in the first sentence of paragraph 4 of the discussion that ‘...a recent review considered the evidence is inconclusive due to the low quality of the research’ citing Malas et al. (2016). We will amend this to start ‘...recent reviews have considered the evidence...’ and additionally cite the reference to the major report in 2018 that the reviewers mention.

In addition to these three concerns, this report noted the importance of the study focusing on quit attempts with a comparable control group – this issue has been highlighted in the 2019 paper by Pierce et al. in Nicotine and Tobacco Research.

In the second sentence of paragraph 4 of the discussion we will add ‘the use of non-comparable control groups’ after ‘the use of unrepresentative populations’.

This analysis showed that the likelihood of a quit attempt was much higher in e-cigarette users in the PATH study (many who started using e-cigarettes did so because they were
trying to quit) than it was in the control population. Thus, the higher probability of making a quit attempt could explain the difference in smoking cessation and so the difference should not be attributed to the use of e-cigarettes.

We already do adjust for aspects of smoking related to quitting in our analyses, as shown in Tables 1 and 3.

However, the authors go further and argue “Problems involve the ... failure to limit attention to established e-cigarette users,” (Para 4 introduction). It is not clear what the authors mean by this? Do they mean that the study population need to have developed a consistent pattern of dual use of cigarettes and e-cigarettes? What is their justification for such a limitation when addressing the stated research question? It is apparent that they do not place such a limitation on their own analyses.

It does not seem sensible to include among e-cigarette users those who have in the past tried them once or twice and abandoned them as they did not like them. The reviewers state that we did not limit attention to established users. This is untrue; that we do limit attention to established users is very clearly stated in the third paragraph of the methods section.

Indeed, the authors have not laid out specific research questions or hypotheses that guide the analyses that they undertake in this paper. This is an important omission.

In the introduction, the first sentence of the final paragraph is ‘Here we describe results from a prospective study aimed at avoiding such weaknesses.’ which might be regarded as a statement of our objectives. However we will insert a sentence after this to read:

‘The main objective of our analyses is to quantify the relationship between e-cigarette use in smokers and subsequent cessation of smoking, with detailed adjustment for the multitude of factors that may differ between e-cigarette users and non-users.’ We will also amend the next sentence to start ‘Our analyses are based on’ rather than ‘It is based on...’.

In the methods, the authors state that analyses are based on individuals with relevant data available at Waves 1, 2 and 3 on smoking and e-cigarette use. They do not mention that the population needed to have made a recent quit attempt. As noted above, unless they demonstrate that the populations that they choose are comparable on this variable, then their study is confounded.

We did not say that the population needed to have made a recent quit attempt, as this was not a requirement in our study, and indeed was not a requirement of a number of the other studies we had cited in our discussion (Berry et al., 2019; Kalkhoran et al., 2019; Verplaetse et al., 2019), though it was in others (Benmarhnia et al., 2018; Watkins et al., 2019). Those who used e-cigarettes at baseline may not at that time have used them intending to quit, but may have found during follow-up that they could meet their nicotine needs without smoking cigarettes. Our analyses compared quit rates
between e-cigarette users and non-users to try to answer the simpler, and highly relevant, question ‘are e-cigarette users more likely to quit?’ We prefer to present results based on the whole population of baseline smokers, thus using a larger sample size than if we restricted attention to quit attempters, and to try to avoid bias by taking into account a range of predictor variables related to quitting.

However we will add a second paragraph in the methods section as follows.

‘Some studies of data from Waves 1 to 3 of the PATH study (Benmarhnia et al., 2018; Pierce et al., 2020a; Watkins et al., 2019) have limited analyses to quit attempters, but others (Berry et al., 2019; Kalkhoran et al., 2019; Verplaetse et al., 2019) have not. Although such a limitation more closely mimics randomized control trials (Pierce et al., 2020b) we prefer not to do so, and to avoid bias by adjusting for aspects of quitting in analyses. Our approach uses a larger sample size and provides results that are more representative of the whole population of baseline smokers’.

As already noted, we intend to carry out some additional analyses limited to quit attempters in the paper being prepared based on data from Waves 1 to 4, though we do note for the reviewers’ information that a preliminary analysis we conducted, based on data from Waves 1 and 2 and limiting attention to those who at Wave 2 had ever made a quit attempt, produced an adjusted odds ratio of 1.20 (95%CI 0.91-1.57) which is very similar to the estimate we give in Table 2 of our paper of 1.23 (0.94-1.61).

The methods are not at all clear about the outcome measure used in this analysis. In their section outlining their main analyses, the authors use the term “quitting during follow-up”. What does this mean? A logical interpretation is that a quit attempt was made in the year prior to the follow-up survey. However, the authors have not addressed the quit attempt data in the methods. Do they use a point prevalence of former smoking at the follow-up survey? If so, how can this be described as successful smoking cessation? This is one of the most critical points in the paper. Most other papers discussing successful quitting require abstinence for either 6 or 12 months at follow-up (see, Gilpin et al. 1997). This is particularly important in an observational study when a person quit at follow-up could have quit only for the day before the survey, for example.

We certainly thought that we had made it clear enough in the methods that we were defining smoking status as at each Wave, and defining quitting based on being a current established smoker at baseline and a former established smoker at follow-up. While we agree that some former smokers may only have quit for a relatively short time, we believe that our method still provides meaningful results. However, we will extend the first sentence of the old fourth paragraph of the methods to read ‘The main analysis for each period relates ever e-cigarette use at baseline to the probability of being an established former smoker at follow-up (referred to subsequently as either “quitting” or “quitting during follow-up”), with adjustment for predictor variables measured at baseline.’

Again, for the reviewers’ information, we repeated our Wave 1 to 2 analysis, redefining quitting as having quit for at least 30 days. This produced an adjusted estimate of 1.26
(95%CI 0.93-1.70) which is very similar to the estimate we give in Table 2 of our paper of 1.23 (0.94-1.61).

The potential confounders in this analysis include those variables that are associated with use of e-cigarettes as well as variables that are associated with successful cessation. The authors omit any discussion of variables associated with the probability of a smoker using an e-cigarette, thus seriously confounding their analyses. At least in a supplement, there should be a summary table of these predictors outlining how they are associated with e-cigarette use.

We will extend the fifth paragraph of the methods section to read as follows:

'The specific predictor variables are listed in the Results section, with fuller details of their definition given in the Extended data. While the variables were chosen as being suggested by the literature as being related to smoking, the Extended data also provides information, based on Wave 1, of their association with ever e-cigarette use. As shown there, ever use was highly significantly (p < 0.001) more frequent in the young and in females, and after adjustment for age and sex, was also highly significantly related to a range of the predictor variables considered, being less frequent in Hispanics and Blacks, and more frequent in those with more income or education, those who ever use other tobacco products, those who have a perceived greater need for tobacco, those who have tried to quit more often, those who plan to quit, those who find it hard to stop smoking and those who have used quitting aids. Users were also clearly more likely to have significant problems more recently with sleeping, anxiety and distress, to see a doctor more often, to use the internet often, and to use various different types of drugs (but not cocaine or crack). At most weak relationships were seen with smoking by family and friends, awareness of the hazards of smoking, use of alcohol, body mass index, or self-perception of physical health or quality of life. Little relationship was also seen between ever e-cigarette use and daily cigarette consumption, a finding which was reported earlier (Lee et al., 2020), where it was suggested that it was explained by smokers taking up e-cigarettes having higher consumption initially, reduced by partial replacement of cigarettes by e-cigarettes.'

We will also, in due course, add to the Extended data a section describing and presenting the output from which the above results are summarized.

Analytic Plan: The analysis plan lays out a stepwise forward selection logistic regression, adjusted for selected covariates. What is unclear is how the authors use step 5 & 6 of their analytic plan in drawing their inferences.

Our inferences are drawn from the results of the step 5 and 6 analyses which, reassuringly, produced the same models. The results in Table 2 compare unadjusted odds ratios with those adjusted for the final (step 5/6) models shown in Table 3.

There is a problem with the use of study weights. For their Wave 2 to Wave 3 analysis, it would seem that the appropriate weights would be the Wave 2 weights,
In fact we did use Wave 2 weights for the Wave 2 to Wave 3 analysis. We will correct the end of the second sentence of the first paragraph of the Methods section to read ‘, and take account of the person-based weights of the baseline population’.

A figure laying out the different analyses with samples sizes (including loss to follow-up) would be very helpful to the reader.

Results: The unadjusted quitting rates by ever use of e-cigarettes should be presented in a table in the results section.

Also, the authors should report the percentage of subjects excluded in the multiple regressions.

We already present in Tables 1 and 2 sample sizes in each of the main analyses. We will add information on the proportion of the baseline population that were not followed up, but do not think that this merits a figure. We will also extend Table 2 to include additional lines to cover the other points made by the reviewers. Thus the revised tables will start with the following lines:

Table 1.
Table 2.

Any reworking of this manuscript should discuss the four recent analyses that address e-cigarettes and smoking using the PATH data. All these papers use appropriate analytic procedures and arrive at opposite conclusions to those of the authors3 - 6.

Of the four references which the reviewers cite, two (Dai and Leventhal, 2019; Everard et al., 2020) relate to relapse, which is outside the scope of the paper, and not quitting, and one of these (Dai and Leventhal, 2019) in any case states that ‘Baseline e-cigarette use was not associated with smoking relapse at follow-up after covariate adjustment.’ We do not propose to cite these two references, as our paper concerns quitting.

One of the other two references the reviewers cite (Pierce et al., 2020a), not published at the time our paper was prepared, describes analyses based on Waves 1 to 3 of the PATH study. We have, in the discussion in paragraphs 3 to 7, already summarized findings from five other analyses based on the PATH study which are consistent with e-cigarette use increasing the probability of quitting cigarettes. To take into account this paper, and to provide further detail in the discussion, we propose to make the following two changes.

First, we will extend the second paragraph of the discussion to read as follows:

‘Six other related analyses based on the first three Waves 1 of the PATH study have previously been published. The first five analyses summarized below (Benmarhnia et al., 2018; Berry et al., 2019; Kalkhoran et al., 2019; Verplaetse et al., 2019; Watkins et al., 2019) are consistent with e-cigarette use increasing the probability of quitting
cigarettes, despite variation in whether Wave 3 data has been used or not, whether analyses are restricted to those attempting quitting at baseline, the definition of abstinence used, the confounding variables adjusted for, and other analytical details. However, the final analysis (Pierce et al., 2020a) only reported a small and non-significant increase in quitting related to e-cigarette use.

Second, we will add a new paragraph about the latest study at the end of the paragraphs describing the results of the first five analyses as follows:

‘A third analysis based on data from Waves 1, 2 and 3 (Pierce et al., 2020a) restricted attention to adult (ages 18+) smokers identified at Wave 1 who reported a quit attempt before Wave 2 and completed Wave 3. 12 month abstinence at Wave 3 among e-cigarette users was slightly but non-significantly reduced as compared both to users of pharmacotherapy to quit or no product.’

The other reference cited by the reviewers (Chen et al., 2020) refers to analyses based on Waves 1 to 4 of the PATH study. Partly because our analyses relate to Waves 1 to 3, and partly because we are currently developing analyses based on Waves 1 to 4 for a further publication, we strongly prefer not to consider analyses that include Wave 4 data in our discussion.

We will also add two extra sentences at the end of the penultimate paragraph of our discussion section, which refers to the planned further paper, as follows:

‘That paper might also consider different definitions of quitting, such as at least 30 day quitting, and investigate the effect of restricting attention to those attempting quitting at baseline. It will also describe and comment on other publications that have used data up to Wave 4’.

Is the work clearly and accurately presented and does it cite the current literature? Partly

It was never intended to consider literature based on analyses using PATH Wave 4 data, or considering relapse, and the huge literature on e-cigarettes from other studies is covered in fair detail.

Is the study design appropriate and is the work technically sound? Are sufficient details of methods and analysis provided to allow replication by others? If applicable, is the statistical analysis and its interpretation appropriate? Are all the source data underlying the results available to ensure full reproducibility? Are the conclusions drawn adequately supported by the results?

We confirm that we have read this submission and believe that we have an appropriate level of expertise to state that we do not consider it to be of an acceptable scientific standard, for reasons outlined above.

We hope that our submission, when the revisions described are made, will now be considered of an acceptable scientific standard.

References
Benmarhnia, T., Pierce, J.P., Leas, E., White, M.M., Strong, D.R., Noble, M.L., Trinidad, D.R.,
2018. Can e-cigarettes and pharmaceutical aids increase smoking cessation and reduce cigarette consumption? Findings from a nationally representative cohort of American smokers. Am. J. Epidemiol. 187, 11, 2397-2404. DOI:10.1093/aje/kwy129.

Berry, K.M., Reynolds, L.M., Collins, J.M., Siegel, M.B., Fetterman, J.L., Hamburg, N.M., Bhatnagar, A., Benjamin, E.J., Stokes, A., 2019. E-cigarette initiation and associated changes in smoking cessation and reduction: the Population Assessment of Tobacco and Health Study, 2013-2015. Tob. Control. 28, 1, 42-49. DOI:10.1136/tobaccocontrol-2017-054108.

Chen, R., Pierce, J.P., Leas, E.C., White, M.M., Kealey, S., Strong, D.R., Trinidad, D.R., Benmarhnia, T., Messer, K., 2020. E-cigarette use to aid long-term smoking cessation in the US: Prospective evidence from the PATH Cohort Study. Am. J. Epidemiol. Published online ahead of print July 27, 2020 (doi: 10.1093/aje/kwa161). DOI:10.1093/aje/kwa161. Erratum appears in Am J Epidemiol. 2020 Sep 12;kwa193. doi: 10.1093/aje/kwa193.

Dai, H., Leventhal, A.M., 2019. Association of electronic cigarette vaping and subsequent smoking relapse among former smokers. Drug Alcohol Depend. 199, 10-17. DOI:10.1016/j.drugalcdep.2019.01.043.

Everard, C.D., Silveira, M.L., Kimmel, H.L., Marshall, D., Blanco, C., Compton, W.M., 2020. Association of electronic nicotine delivery system use with cigarette smoking relapse among former smokers in the United States. JAMA Netw. Open. 3, 6, e204813. DOI:10.1001/jamanetworkopen.2020.4813.

Halpern, S.D., Harhay, M.O., Saulsgiver, K., Brophy, C., Troxel, A.B., Volpp, K.G., 2018. A pragmatic trial of e-cigarettes, incentives, and drugs for smoking cessation. N. Engl. J. Med. 378, 24, 2302-2310. DOI:10.1056/NEJMsa1715757.

Kalkhoran, S., Chang, Y., Rigotti, N.A., 2019. E-cigarettes and smoking cessation in smokers with chronic conditions. Am. J. Prev. Med. 57, 6, 786-791. DOI:10.1016/j.amjepre.2019.08.017.

Lee, P., Fry, J., Forey, B., Coombs, K.J., Thornton, A.J., 2020. Cigarette consumption in adult dual users of cigarettes and e-cigarettes: a review of the evidence, including new results from the PATH study [version 1; peer review: awaiting peer review] F1000Res. 9, 630. DOI:10.12688/f1000research.24589.1.

Malas, M., van der Tempel, J., Schwartz, R., Minichiello, A., Lightfoot, C., Noormohamed, A., Andrews, J., Zawertailo, L., Ferrence, R., 2016. Electronic cigarettes for smoking cessation: A systematic review. Nicotine Tob. Res. 18, 10, 1926-1936. DOI:10.1093/ntr/ntw119.

Pierce, J.P., et al., 2020a. Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16. PLoS One. 15, 9, e0237938. DOI:10.1371/journal.pone.0237938.

Pierce, J.P., Messer, K., Leas, E.C., Kealey, S., White, M.M., Benmarhnia, T., 2020b. A source of bias in studies of e-cigarettes and smoking cessation. Nicotine Tob. Res. 22, 5, 861-862. DOI:10.1093/ntr/ntz143.
Verplaetse, T.L., Moore, K.E., Pittman, B.P., Roberts, W., Oberleitner, L.M., Peltier, M.K.R., Hacker, R., Cosgrove, K.P., McKee, S.A., 2019. Intersection of e-cigarette use and gender on transitions in cigarette smoking status: Findings across Waves 1 and 2 of the Population Assessment of Tobacco and Health Study. Nicotine Tob. Res. 21, 10, 1423-1428. DOI:10.1093/ntr/nty187.

Watkins, S.L., Thrul, J., Max, W., Ling, P.M., 2019. Real-world effectiveness of smoking cessation strategies for young and older adults: Findings from a nationally representative cohort. Nicotine Tob. Res. 22, 9, 1560-1568. DOI:10.1093/ntr/ntz223.

**Competing Interests:** None other than already stated in the paper.